Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15665755,serum concentrations,"The median serum concentrations of risperidone plus 9-hydroxyrisperidone were 38 nmol/L 12-14 days after a intramuscular dose of 25 mg/14 days, 67 nmol/L after a dose of 37.5 mg/14 days, 99 nmol/L after a dose of 50 mg/14 days, and 148 nmol/L after a dose of 75 mg/14 days.",Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15665755/),,38,2301,DB00734,Risperidone
,15665755,serum concentrations,"The median serum concentrations of risperidone plus 9-hydroxyrisperidone were 38 nmol/L 12-14 days after a intramuscular dose of 25 mg/14 days, 67 nmol/L after a dose of 37.5 mg/14 days, 99 nmol/L after a dose of 50 mg/14 days, and 148 nmol/L after a dose of 75 mg/14 days.",Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15665755/),[nM] / [l],67,2302,DB00734,Risperidone
,15665755,serum concentrations,"The median serum concentrations of risperidone plus 9-hydroxyrisperidone were 38 nmol/L 12-14 days after a intramuscular dose of 25 mg/14 days, 67 nmol/L after a dose of 37.5 mg/14 days, 99 nmol/L after a dose of 50 mg/14 days, and 148 nmol/L after a dose of 75 mg/14 days.",Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15665755/),[nM] / [l],99,2303,DB00734,Risperidone
,15665755,serum concentrations,"The median serum concentrations of risperidone plus 9-hydroxyrisperidone were 38 nmol/L 12-14 days after a intramuscular dose of 25 mg/14 days, 67 nmol/L after a dose of 37.5 mg/14 days, 99 nmol/L after a dose of 50 mg/14 days, and 148 nmol/L after a dose of 75 mg/14 days.",Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15665755/),[nM] / [l],148,2304,DB00734,Risperidone
,15665755,C/D ratio,The median C/D ratio for risperidone plus 9-hydroxy-risperidone was 22.2 (nmol/L)/(mg/d).,Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15665755/),[l·nmol] / [d·mg],22.2,2305,DB00734,Risperidone
,15665755,C/D ratio,"In the group on oral medication, the median C/D ratio was 18.6 (nmol/L)/(mg/d).",Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15665755/),[l·nM] / [d·mg],18.6,2306,DB00734,Risperidone
less,32726002,Relative attenuation ratios,"Relative attenuation ratios were less than 1, indicating a slower central versus peripheral attenuation, across the time points for all antipsychotic types and doses with only a few exceptions.",Dissociation in Pharmacokinetic Attenuation Between Central Dopamine D2 Receptor Occupancy and Peripheral Blood Concentration of Antipsychotics: A Systematic Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32726002/),,1,3875,DB00734,Risperidone
,17007366,flow rate,"Risperidone and the internal standard, diphenhydramine, were isolated from plasma by liquid-liquid extraction with etherdichloromethane (3:2, v/v) , then chromatographed on a Zorbax Extend-C18 column (150 mm x 4.6 mm ID, 5 microm) using a mobile phase consisted of acetonitrile-water-formic acid (40:60: 0.5, v/v), at a flow rate of 0.7 mL x min(-1).",[Determination of risperidone in human plasma by liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17007366/),[ml] / [min],0.7,7054,DB00734,Risperidone
,31774943,Dose-corrected AM levels,Dose-corrected AM levels were more than doubled in the 30-60 mL/min/1.73 m² group compared to the > 90-120 mL/min/1.73 m² group (mean ± SD = 22.2 ± 14.0 [ng/mL]/[mg/d] vs 10.1 ± 7.7 [ng/mL]/[mg/d]).,Influence of Kidney Function on Serum Risperidone Concentrations in Patients Treated With Risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31774943/),[ng] / [ml],22.2,7110,DB00734,Risperidone
,31774943,Dose-corrected AM levels,Dose-corrected AM levels were more than doubled in the 30-60 mL/min/1.73 m² group compared to the > 90-120 mL/min/1.73 m² group (mean ± SD = 22.2 ± 14.0 [ng/mL]/[mg/d] vs 10.1 ± 7.7 [ng/mL]/[mg/d]).,Influence of Kidney Function on Serum Risperidone Concentrations in Patients Treated With Risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31774943/),[ng] / [ml],10.1,7111,DB00734,Risperidone
,17614267,C(max),"After a 12.5mg/kg IM injection of a 25mg/g RSP-SAIB in situ system, the C(max) was markedly reduced from 944.1+/-80.2 to 330.4+/-33.6ng/ml by increasing PLA from 1% to 10% (w/w), the T(max) were prolonged from 2 to 4.3+/-2.0h, and the area under the curve from day 0 to 2 (AUC(0-2day)) was reduced significantly from 16294.8+/-3946.4 to 7025.3+/-1979.2ngh/ml.",In vivo evaluation of risperidone-SAIB in situ system as a sustained release delivery system in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17614267/),[ng] / [ml],944.1,9969,DB00734,Risperidone
,17614267,C(max),"After a 12.5mg/kg IM injection of a 25mg/g RSP-SAIB in situ system, the C(max) was markedly reduced from 944.1+/-80.2 to 330.4+/-33.6ng/ml by increasing PLA from 1% to 10% (w/w), the T(max) were prolonged from 2 to 4.3+/-2.0h, and the area under the curve from day 0 to 2 (AUC(0-2day)) was reduced significantly from 16294.8+/-3946.4 to 7025.3+/-1979.2ngh/ml.",In vivo evaluation of risperidone-SAIB in situ system as a sustained release delivery system in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17614267/),[ng] / [ml],330.4,9970,DB00734,Risperidone
,17614267,T(max),"After a 12.5mg/kg IM injection of a 25mg/g RSP-SAIB in situ system, the C(max) was markedly reduced from 944.1+/-80.2 to 330.4+/-33.6ng/ml by increasing PLA from 1% to 10% (w/w), the T(max) were prolonged from 2 to 4.3+/-2.0h, and the area under the curve from day 0 to 2 (AUC(0-2day)) was reduced significantly from 16294.8+/-3946.4 to 7025.3+/-1979.2ngh/ml.",In vivo evaluation of risperidone-SAIB in situ system as a sustained release delivery system in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17614267/),h,2,9971,DB00734,Risperidone
,17614267,T(max),"After a 12.5mg/kg IM injection of a 25mg/g RSP-SAIB in situ system, the C(max) was markedly reduced from 944.1+/-80.2 to 330.4+/-33.6ng/ml by increasing PLA from 1% to 10% (w/w), the T(max) were prolonged from 2 to 4.3+/-2.0h, and the area under the curve from day 0 to 2 (AUC(0-2day)) was reduced significantly from 16294.8+/-3946.4 to 7025.3+/-1979.2ngh/ml.",In vivo evaluation of risperidone-SAIB in situ system as a sustained release delivery system in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17614267/),h,4.3,9972,DB00734,Risperidone
,17614267,area under the curve from day 0 to 2 (AUC(0-2day)),"After a 12.5mg/kg IM injection of a 25mg/g RSP-SAIB in situ system, the C(max) was markedly reduced from 944.1+/-80.2 to 330.4+/-33.6ng/ml by increasing PLA from 1% to 10% (w/w), the T(max) were prolonged from 2 to 4.3+/-2.0h, and the area under the curve from day 0 to 2 (AUC(0-2day)) was reduced significantly from 16294.8+/-3946.4 to 7025.3+/-1979.2ngh/ml.",In vivo evaluation of risperidone-SAIB in situ system as a sustained release delivery system in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17614267/),[ngh] / [ml],16294.8,9973,DB00734,Risperidone
,17614267,area under the curve from day 0 to 2 (AUC(0-2day)),"After a 12.5mg/kg IM injection of a 25mg/g RSP-SAIB in situ system, the C(max) was markedly reduced from 944.1+/-80.2 to 330.4+/-33.6ng/ml by increasing PLA from 1% to 10% (w/w), the T(max) were prolonged from 2 to 4.3+/-2.0h, and the area under the curve from day 0 to 2 (AUC(0-2day)) was reduced significantly from 16294.8+/-3946.4 to 7025.3+/-1979.2ngh/ml.",In vivo evaluation of risperidone-SAIB in situ system as a sustained release delivery system in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17614267/),[ngh] / [ml],7025.3,9974,DB00734,Risperidone
,12107617,Plasma concentrations,Plasma concentrations of risperidone and 9-hydroxyrisperidone during carbamazepine coadministration (2.5+/-3.6 ng/ml and 19.4+/-4.1 ng/ml) were significantly ( P<0.01) lower than those before carbamazepine coadministration (5.0+/-7.9 ng/ml and 34.6+/-9.8 ng/ml).,Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12107617/),[ng] / [ml],2.5,11989,DB00734,Risperidone
,12107617,Plasma concentrations,Plasma concentrations of risperidone and 9-hydroxyrisperidone during carbamazepine coadministration (2.5+/-3.6 ng/ml and 19.4+/-4.1 ng/ml) were significantly ( P<0.01) lower than those before carbamazepine coadministration (5.0+/-7.9 ng/ml and 34.6+/-9.8 ng/ml).,Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12107617/),[ng] / [ml],19.4,11990,DB00734,Risperidone
,12107617,Plasma concentrations,Plasma concentrations of risperidone and 9-hydroxyrisperidone during carbamazepine coadministration (2.5+/-3.6 ng/ml and 19.4+/-4.1 ng/ml) were significantly ( P<0.01) lower than those before carbamazepine coadministration (5.0+/-7.9 ng/ml and 34.6+/-9.8 ng/ml).,Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12107617/),[ng] / [ml],5.0,11991,DB00734,Risperidone
,12107617,Plasma concentrations,Plasma concentrations of risperidone and 9-hydroxyrisperidone during carbamazepine coadministration (2.5+/-3.6 ng/ml and 19.4+/-4.1 ng/ml) were significantly ( P<0.01) lower than those before carbamazepine coadministration (5.0+/-7.9 ng/ml and 34.6+/-9.8 ng/ml).,Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12107617/),[ng] / [ml],34.6,11992,DB00734,Risperidone
,27749254,Maximal plasma concentration (cmax),"Maximal plasma concentration (cmax) and the time to reach cmax (tmax) were 15.2 μg mL-1 and 5 min for the nasal gel, 3.6 μg mL-1 and 30 min for the oral drug suspension, respectively.",Preparation and in vivo evaluation of a gel-based nasal delivery system for risperidone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27749254/),[μg] / [ml],15.2,12226,DB00734,Risperidone
,27749254,Maximal plasma concentration (cmax),"Maximal plasma concentration (cmax) and the time to reach cmax (tmax) were 15.2 μg mL-1 and 5 min for the nasal gel, 3.6 μg mL-1 and 30 min for the oral drug suspension, respectively.",Preparation and in vivo evaluation of a gel-based nasal delivery system for risperidone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27749254/),min,5,12227,DB00734,Risperidone
,27749254,Maximal plasma concentration (cmax),"Maximal plasma concentration (cmax) and the time to reach cmax (tmax) were 15.2 μg mL-1 and 5 min for the nasal gel, 3.6 μg mL-1 and 30 min for the oral drug suspension, respectively.",Preparation and in vivo evaluation of a gel-based nasal delivery system for risperidone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27749254/),[μg] / [ml],3.6,12228,DB00734,Risperidone
,27749254,time to reach cmax (tmax),"Maximal plasma concentration (cmax) and the time to reach cmax (tmax) were 15.2 μg mL-1 and 5 min for the nasal gel, 3.6 μg mL-1 and 30 min for the oral drug suspension, respectively.",Preparation and in vivo evaluation of a gel-based nasal delivery system for risperidone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27749254/),min,5,12229,DB00734,Risperidone
,27749254,time to reach cmax (tmax),"Maximal plasma concentration (cmax) and the time to reach cmax (tmax) were 15.2 μg mL-1 and 5 min for the nasal gel, 3.6 μg mL-1 and 30 min for the oral drug suspension, respectively.",Preparation and in vivo evaluation of a gel-based nasal delivery system for risperidone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27749254/),min,30,12230,DB00734,Risperidone
up to,27749254,Relative bioavailability,Relative bioavailability of the drug nasal preparation to the oral suspension was up to 1600.0 %.,Preparation and in vivo evaluation of a gel-based nasal delivery system for risperidone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27749254/),%,1600.0,12231,DB00734,Risperidone
,30628010,Tmax,"VAL401 provided the following key pharmacokinetic parameters for the risperidone plasma concentration after a single 2-mg dose of VAL401, with results normalised to a dosage of 1 mg for comparison with literature values: Tmax, 2 h; Cmax, 8 ng/ml; half-life, 3.5 h; area under the plasma concentration-time curve from time zero to infinity (AUC0-∞), 58.2 ng h2/mL.","Clinical Pharmacokinetics of a Lipid-Based Formulation of Risperidone, VAL401: Analysis of a Single Dose in an Open-Label Trial of Late-Stage Cancer Patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30628010/),h,2,17004,DB00734,Risperidone
,30628010,Cmax,"VAL401 provided the following key pharmacokinetic parameters for the risperidone plasma concentration after a single 2-mg dose of VAL401, with results normalised to a dosage of 1 mg for comparison with literature values: Tmax, 2 h; Cmax, 8 ng/ml; half-life, 3.5 h; area under the plasma concentration-time curve from time zero to infinity (AUC0-∞), 58.2 ng h2/mL.","Clinical Pharmacokinetics of a Lipid-Based Formulation of Risperidone, VAL401: Analysis of a Single Dose in an Open-Label Trial of Late-Stage Cancer Patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30628010/),[ng] / [ml],8,17005,DB00734,Risperidone
,30628010,half-life,"VAL401 provided the following key pharmacokinetic parameters for the risperidone plasma concentration after a single 2-mg dose of VAL401, with results normalised to a dosage of 1 mg for comparison with literature values: Tmax, 2 h; Cmax, 8 ng/ml; half-life, 3.5 h; area under the plasma concentration-time curve from time zero to infinity (AUC0-∞), 58.2 ng h2/mL.","Clinical Pharmacokinetics of a Lipid-Based Formulation of Risperidone, VAL401: Analysis of a Single Dose in an Open-Label Trial of Late-Stage Cancer Patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30628010/),h,3.5,17006,DB00734,Risperidone
,30628010,area under the plasma concentration-time curve from time zero to infinity (AUC0-∞),"VAL401 provided the following key pharmacokinetic parameters for the risperidone plasma concentration after a single 2-mg dose of VAL401, with results normalised to a dosage of 1 mg for comparison with literature values: Tmax, 2 h; Cmax, 8 ng/ml; half-life, 3.5 h; area under the plasma concentration-time curve from time zero to infinity (AUC0-∞), 58.2 ng h2/mL.","Clinical Pharmacokinetics of a Lipid-Based Formulation of Risperidone, VAL401: Analysis of a Single Dose in an Open-Label Trial of Late-Stage Cancer Patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30628010/),[h2·ng] / [ml],58.2,17007,DB00734,Risperidone
,17825699,C(max),"Mean (SD) values for C(max), t(1/2), and AUC 0 to 12 hours for risperidone in plasma were 15.9 (22.2) ng/mL, 3.0 (2.3) h, and 92.1 (200.6) ng x h/mL, respectively.",Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825699/),[ng] / [ml],15.9,20859,DB00734,Risperidone
,17825699,t(1/2),"Mean (SD) values for C(max), t(1/2), and AUC 0 to 12 hours for risperidone in plasma were 15.9 (22.2) ng/mL, 3.0 (2.3) h, and 92.1 (200.6) ng x h/mL, respectively.",Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825699/),h,3.0,20860,DB00734,Risperidone
,17825699,AUC 0 to 12 hours,"Mean (SD) values for C(max), t(1/2), and AUC 0 to 12 hours for risperidone in plasma were 15.9 (22.2) ng/mL, 3.0 (2.3) h, and 92.1 (200.6) ng x h/mL, respectively.",Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825699/),[h·ng] / [ml],92.1,20861,DB00734,Risperidone
,17825699,C(max),"Mean (SD) plasma enantiomer values for C(max) and AUC calculated up to the last observation were: (+)-9-OH-risperidone, 13.6 (10.0) ng/mL and 73.6 (52.3) ng x h/mL; (-)-9-OH-risperidone, 4.9 (3.1) ng/mL and 29.3 (19.1) ng x h/mL.",Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825699/),[ng] / [ml],13.6,20862,DB00734,Risperidone
,17825699,C(max),"Mean (SD) plasma enantiomer values for C(max) and AUC calculated up to the last observation were: (+)-9-OH-risperidone, 13.6 (10.0) ng/mL and 73.6 (52.3) ng x h/mL; (-)-9-OH-risperidone, 4.9 (3.1) ng/mL and 29.3 (19.1) ng x h/mL.",Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825699/),[ng] / [ml],4.9,20863,DB00734,Risperidone
,17825699,AUC,"Mean (SD) plasma enantiomer values for C(max) and AUC calculated up to the last observation were: (+)-9-OH-risperidone, 13.6 (10.0) ng/mL and 73.6 (52.3) ng x h/mL; (-)-9-OH-risperidone, 4.9 (3.1) ng/mL and 29.3 (19.1) ng x h/mL.",Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825699/),[h·ng] / [ml],73.6,20864,DB00734,Risperidone
,17825699,AUC,"Mean (SD) plasma enantiomer values for C(max) and AUC calculated up to the last observation were: (+)-9-OH-risperidone, 13.6 (10.0) ng/mL and 73.6 (52.3) ng x h/mL; (-)-9-OH-risperidone, 4.9 (3.1) ng/mL and 29.3 (19.1) ng x h/mL.",Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825699/),[h·ng] / [ml],29.3,20865,DB00734,Risperidone
,27593571,vesicle size,The mean vesicle size of optimized liposomes ranged from 90 to 100nm with low polydispersity index (<0.5).,Development of risperidone liposomes for brain targeting through intranasal route. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27593571/),nm,90 to 100,22751,DB00734,Risperidone
,27593571,entrapment efficiency,"The entrapment efficiency of optimized liposomes was between 50 and 60%, functionalized liposomes showed maximum entrapment.",Development of risperidone liposomes for brain targeting through intranasal route. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27593571/),%,50 and 60,22752,DB00734,Risperidone
,11823895,terminal elimination half-life (t(1/2) ),The terminal elimination half-life (t(1/2) ) of RSP after the RSP dose was longest in the liver (17.6 h) and shortest in the spleen (1.2 h).,"Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823895/),h,17.6,24560,DB00734,Risperidone
,11823895,terminal elimination half-life (t(1/2) ),The terminal elimination half-life (t(1/2) ) of RSP after the RSP dose was longest in the liver (17.6 h) and shortest in the spleen (1.2 h).,"Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823895/),h,1.2,24561,DB00734,Risperidone
,11823895,t(1/2),The t(1/2)of 9-OHRSP after the RSP dose was shorter in plasma (3.4 h) and other tissues (approximately 8-11 h) than that for RSP but it was longer in the spleen.,"Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823895/),h,3.4,24562,DB00734,Risperidone
,11823895,t(1/2),The t(1/2)of 9-OHRSP after the RSP dose was shorter in plasma (3.4 h) and other tissues (approximately 8-11 h) than that for RSP but it was longer in the spleen.,"Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823895/),h,8-11,24563,DB00734,Risperidone
,21034370,time to peak plasma concentration,"time to peak plasma concentration occurs in 2 - 4 h but elimination half-life is 18 h for extensive CYP2D6 metabolizers and 33 h for poor CYP2D6 metabolizers, suggesting that once or twice daily dosing would be feasible.","Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034370/),h,2 - 4,26685,DB00734,Risperidone
,21034370,elimination half-life,"time to peak plasma concentration occurs in 2 - 4 h but elimination half-life is 18 h for extensive CYP2D6 metabolizers and 33 h for poor CYP2D6 metabolizers, suggesting that once or twice daily dosing would be feasible.","Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034370/),h,18,26686,DB00734,Risperidone
,21034370,elimination half-life,"time to peak plasma concentration occurs in 2 - 4 h but elimination half-life is 18 h for extensive CYP2D6 metabolizers and 33 h for poor CYP2D6 metabolizers, suggesting that once or twice daily dosing would be feasible.","Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034370/),h,33,26687,DB00734,Risperidone
,15788540,kinact,"We have predicted the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine from in vitro inactivation kinetics (kinact 0.17 min(-1), unbound KI 0.315 microM), in vivo inhibitor concentrations, and an estimated CYP2D6 degradation half-life of 51 h, using a mathematical model of mechanism-based inhibition.",In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15788540/),1/[min],0.17,28928,DB00734,Risperidone
,15788540,unbound KI,"We have predicted the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine from in vitro inactivation kinetics (kinact 0.17 min(-1), unbound KI 0.315 microM), in vivo inhibitor concentrations, and an estimated CYP2D6 degradation half-life of 51 h, using a mathematical model of mechanism-based inhibition.",In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15788540/),μM,0.315,28929,DB00734,Risperidone
,15788540,degradation half-life,"We have predicted the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine from in vitro inactivation kinetics (kinact 0.17 min(-1), unbound KI 0.315 microM), in vivo inhibitor concentrations, and an estimated CYP2D6 degradation half-life of 51 h, using a mathematical model of mechanism-based inhibition.",In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15788540/),h,51,28930,DB00734,Risperidone
,15788540,degradation half-life,Simulation of the sensitivities of these predictions to model inputs suggests a 2-fold underprediction of interaction magnitude when a CYP2D6 degradation half-life of 14 h (reported for rat CYP3A) is used.,In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15788540/),h,14,28931,DB00734,Risperidone
,27342643,K i,ITI-214 inhibited PDE1A (K i = 33 pmol) with >1000-fold selectivity for the nearest other PDE family (PDE4D) and displayed minimal off-target binding interactions in a 70-substrate selectivity profile.,"Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27342643/),pM,33,29894,DB00734,Risperidone
,17702401,Rate constant,"Rate constant of RIP conversion to 9-hydroxyrisperidone was (0.12 +/- 0.08) h(-1) and (0.014 +/- 0.007) h(-1) for EM and IM, respectively.",[Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17702401/),1/[h],0.12,33431,DB00734,Risperidone
,17702401,Rate constant,"Rate constant of RIP conversion to 9-hydroxyrisperidone was (0.12 +/- 0.08) h(-1) and (0.014 +/- 0.007) h(-1) for EM and IM, respectively.",[Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17702401/),1/[h],0.014,33432,DB00734,Risperidone
,17702401,Elimination rate constants,"Elimination rate constants of RIP were (0.25 +/- 0.18) and (0.05 +/- 0.23) h(-1) for EM and IM, respectively.",[Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17702401/),1/[h],0.25,33433,DB00734,Risperidone
,17702401,Elimination rate constants,"Elimination rate constants of RIP were (0.25 +/- 0.18) and (0.05 +/- 0.23) h(-1) for EM and IM, respectively.",[Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17702401/),1/[h],0.05,33434,DB00734,Risperidone
,26209070,zeta potential,"From the established design space and stability data, promising risperidone-loaded nanoemulsions (mean size about 160 nm, size distribution <0.15, zeta potential around -50 mV), containing sodium oleate in the aqueous phase and polysorbate 80, poloxamer 188 or Solutol(®) HS15 as co-emulsifier, were produced by hot homogenization and their ability to improve risperidone delivery to the brain was assessed in rats.","Parenteral nanoemulsions as promising carriers for brain delivery of risperidone: Design, characterization and in vivo pharmacokinetic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26209070/),m,50,48285,DB00734,Risperidone
,22888277,half-life,"Due to the long half-life of paliperidone palmitate (25-49 days), putative therapeutic plasma concentrations persisted longest in simulated cases of complete discontinuation or treatment interruption.",Management of antipsychotic treatment discontinuation and interruptions using model-based simulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22888277/),d,25-49,51826,DB00734,Risperidone
,29112001,tmax,"The mean Cmax of the active moiety was achieved 24-48 h (tmax) after each administration, regardless of injection site.","A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29112001/),h,24-48,52152,DB00734,Risperidone
,22929407,Clearance,"Clearance estimates in the mixture model were poor metabolizer 9.38 L/h, intermediate metabolizer 29.2 L/h, and extensive metabolizer 37.4 L/h.",Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22929407/),[l] / [h],9.38,52217,DB00734,Risperidone
,22929407,Clearance,"Clearance estimates in the mixture model were poor metabolizer 9.38 L/h, intermediate metabolizer 29.2 L/h, and extensive metabolizer 37.4 L/h.",Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22929407/),[l] / [h],29.2,52218,DB00734,Risperidone
,22929407,Clearance,"Clearance estimates in the mixture model were poor metabolizer 9.38 L/h, intermediate metabolizer 29.2 L/h, and extensive metabolizer 37.4 L/h.",Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22929407/),[l] / [h],37.4,52219,DB00734,Risperidone
,15355124,oral clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],22-36,55128,DB00734,Risperidone
,15355124,renal clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],10-20,55129,DB00734,Risperidone
,15355124,half-life,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),h,19-25,55130,DB00734,Risperidone
,15355124,absolute bioavailability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55131,DB00734,Risperidone
,15355124,oral availability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55132,DB00734,Risperidone
,26077999,burst release,Ris-m-SAIB depot showed a low burst release (0.64%) and a reduced in vitro drug release rate due to the encapsulation of most drug in microspheres.,A Uniform Ultra-Small Microsphere/SAIB Hybrid Depot with Low Burst Release for Long-Term Continuous Drug Release. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26077999/),%,0.64,60267,DB00734,Risperidone
,26077999,degradation t1/2,Ris-m-SAIB depot degraded gradually with a degradation t1/2 of 54.6 days and exhibited good biocompatibility in vivo.,A Uniform Ultra-Small Microsphere/SAIB Hybrid Depot with Low Burst Release for Long-Term Continuous Drug Release. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26077999/),d,54.6,60268,DB00734,Risperidone
,7542676,absolute oral bioavailability,"The absolute oral bioavailability of risperidone is nearly 70%, and after oral administration, it is rapidly absorbed with the plasma level reaching a peak at about 1 h.","A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7542676/),%,70,63037,DB00734,Risperidone
,33957192,inhibition constants,"Experiments in vitro indicated that CLZ competitively inhibited the conversion of RIS to 9-hydroxy-RIS with the inhibition constants of 1.36 and 3.0 μM in rat and human liver microsomes, respectively.",Clozapine affects the pharmacokinetics of risperidone and inhibits its metabolism and P-glycoprotein-mediated transport in vivo and in vitro: A safety attention to antipsychotic polypharmacy with clozapine and risperidone. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33957192/),μM,1.36,66266,DB00734,Risperidone
,33957192,inhibition constants,"Experiments in vitro indicated that CLZ competitively inhibited the conversion of RIS to 9-hydroxy-RIS with the inhibition constants of 1.36 and 3.0 μM in rat and human liver microsomes, respectively.",Clozapine affects the pharmacokinetics of risperidone and inhibits its metabolism and P-glycoprotein-mediated transport in vivo and in vitro: A safety attention to antipsychotic polypharmacy with clozapine and risperidone. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33957192/),μM,3.0,66267,DB00734,Risperidone
,29404931,AUClast,"The pharmacokinetic parameters of AUClast, AUC∞ and Cmax for the 18 subjects after a single oral dose of the trial or reference preparation were 216.1 ± 88.7 and 220.5 ± 96.8 ng·h/mL; 221.6 ± 93.1 and 226.4 ± 103.5 ng·h/mL; 36.7 ± 10.3 and 36.0 ± 10.2 ng/mL, respectively.",Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404931/),[h·ng] / [ml],216.1,68262,DB00734,Risperidone
,29404931,AUC∞,"The pharmacokinetic parameters of AUClast, AUC∞ and Cmax for the 18 subjects after a single oral dose of the trial or reference preparation were 216.1 ± 88.7 and 220.5 ± 96.8 ng·h/mL; 221.6 ± 93.1 and 226.4 ± 103.5 ng·h/mL; 36.7 ± 10.3 and 36.0 ± 10.2 ng/mL, respectively.",Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404931/),[h·ng] / [ml],220.5,68263,DB00734,Risperidone
,29404931,AUC∞,"The pharmacokinetic parameters of AUClast, AUC∞ and Cmax for the 18 subjects after a single oral dose of the trial or reference preparation were 216.1 ± 88.7 and 220.5 ± 96.8 ng·h/mL; 221.6 ± 93.1 and 226.4 ± 103.5 ng·h/mL; 36.7 ± 10.3 and 36.0 ± 10.2 ng/mL, respectively.",Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404931/),[h·ng] / [ml],221.6,68264,DB00734,Risperidone
,29404931,AUC∞,"The pharmacokinetic parameters of AUClast, AUC∞ and Cmax for the 18 subjects after a single oral dose of the trial or reference preparation were 216.1 ± 88.7 and 220.5 ± 96.8 ng·h/mL; 221.6 ± 93.1 and 226.4 ± 103.5 ng·h/mL; 36.7 ± 10.3 and 36.0 ± 10.2 ng/mL, respectively.",Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404931/),[h·ng] / [ml],226.4,68265,DB00734,Risperidone
,29404931,AUC∞,"The pharmacokinetic parameters of AUClast, AUC∞ and Cmax for the 18 subjects after a single oral dose of the trial or reference preparation were 216.1 ± 88.7 and 220.5 ± 96.8 ng·h/mL; 221.6 ± 93.1 and 226.4 ± 103.5 ng·h/mL; 36.7 ± 10.3 and 36.0 ± 10.2 ng/mL, respectively.",Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404931/),[ng] / [ml],36.7,68266,DB00734,Risperidone
,29404931,Cmax,"The pharmacokinetic parameters of AUClast, AUC∞ and Cmax for the 18 subjects after a single oral dose of the trial or reference preparation were 216.1 ± 88.7 and 220.5 ± 96.8 ng·h/mL; 221.6 ± 93.1 and 226.4 ± 103.5 ng·h/mL; 36.7 ± 10.3 and 36.0 ± 10.2 ng/mL, respectively.",Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404931/),[h·ng] / [ml],226.4,68267,DB00734,Risperidone
,29404931,Cmax,"The pharmacokinetic parameters of AUClast, AUC∞ and Cmax for the 18 subjects after a single oral dose of the trial or reference preparation were 216.1 ± 88.7 and 220.5 ± 96.8 ng·h/mL; 221.6 ± 93.1 and 226.4 ± 103.5 ng·h/mL; 36.7 ± 10.3 and 36.0 ± 10.2 ng/mL, respectively.",Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404931/),[ng] / [ml],36.7,68268,DB00734,Risperidone
,29404931,Cmax,"The pharmacokinetic parameters of AUClast, AUC∞ and Cmax for the 18 subjects after a single oral dose of the trial or reference preparation were 216.1 ± 88.7 and 220.5 ± 96.8 ng·h/mL; 221.6 ± 93.1 and 226.4 ± 103.5 ng·h/mL; 36.7 ± 10.3 and 36.0 ± 10.2 ng/mL, respectively.",Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404931/),[ng] / [ml],36.0,68269,DB00734,Risperidone
,15496223,AUC(0-24 h),Donepezil PK parameters were similar between patients taking donepezil HCl + risperidone (AUC(0-24 h) = 329.0 +/- 17.2 ng x h ml(-1)) and controls taking donepezil HCl alone (AUC(0-24 h) = 354.7 +/- 28.2 ng x h ml(-1)).,Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496223/),[h·ng] / [ml],329.0,68734,DB00734,Risperidone
,15496223,AUC(0-24 h),Donepezil PK parameters were similar between patients taking donepezil HCl + risperidone (AUC(0-24 h) = 329.0 +/- 17.2 ng x h ml(-1)) and controls taking donepezil HCl alone (AUC(0-24 h) = 354.7 +/- 28.2 ng x h ml(-1)).,Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496223/),[h·ng] / [ml],354.7,68735,DB00734,Risperidone
,15496223,AUC(0-12 h,"Pharmacokinetic parameters for risperidone and 9-OH risperidone were not altered in patients with schizophrenia after 7 days of donepezil HCl administration (AUC(0-12 h) standardized by dose: risperidone = 59.6 +/- 16.3 ng.h ml(-1) at day 0, 56.0 +/- 15.8 ng x h ml(-1) at day 7; 9-OH risperidone = 162.1 +/- 19.2 ng x h ml(-1) at day 0, 163.3 +/- 15.0 ng x h ml(-1) at day 7).",Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496223/),[h·ng] / [ml],59.6,68736,DB00734,Risperidone
,15496223,AUC(0-12 h,"Pharmacokinetic parameters for risperidone and 9-OH risperidone were not altered in patients with schizophrenia after 7 days of donepezil HCl administration (AUC(0-12 h) standardized by dose: risperidone = 59.6 +/- 16.3 ng.h ml(-1) at day 0, 56.0 +/- 15.8 ng x h ml(-1) at day 7; 9-OH risperidone = 162.1 +/- 19.2 ng x h ml(-1) at day 0, 163.3 +/- 15.0 ng x h ml(-1) at day 7).",Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496223/),[h·ng] / [ml],56.0,68737,DB00734,Risperidone
,15496223,AUC(0-12 h,"Pharmacokinetic parameters for risperidone and 9-OH risperidone were not altered in patients with schizophrenia after 7 days of donepezil HCl administration (AUC(0-12 h) standardized by dose: risperidone = 59.6 +/- 16.3 ng.h ml(-1) at day 0, 56.0 +/- 15.8 ng x h ml(-1) at day 7; 9-OH risperidone = 162.1 +/- 19.2 ng x h ml(-1) at day 0, 163.3 +/- 15.0 ng x h ml(-1) at day 7).",Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496223/),[h·ng] / [ml],162.1,68738,DB00734,Risperidone
,15496223,AUC(0-12 h,"Pharmacokinetic parameters for risperidone and 9-OH risperidone were not altered in patients with schizophrenia after 7 days of donepezil HCl administration (AUC(0-12 h) standardized by dose: risperidone = 59.6 +/- 16.3 ng.h ml(-1) at day 0, 56.0 +/- 15.8 ng x h ml(-1) at day 7; 9-OH risperidone = 162.1 +/- 19.2 ng x h ml(-1) at day 0, 163.3 +/- 15.0 ng x h ml(-1) at day 7).",Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496223/),[h·ng] / [ml],163.3,68739,DB00734,Risperidone
more,22696224,fraction absorbed,"Since the fraction absorbed of risperidone in simulation was more than 90% with low water solubility, the drug met the criteria of class II of the Biopharmaceutics Classification System.",Developing in vitro-in vivo correlation of risperidone immediate release tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22696224/),%,90,68937,DB00734,Risperidone
,29121571,flow rate,"The extracted samples were separated on Acquity BEH™ C18 column (100×2.1mm, 1.7μm) using mobile phase elution of acetonitrile: 20mM ammonium acetate (80:20, v/v) at a flow rate of 0.3mLmin-1.",High throughput μ-SPE based elution coupled with UPLC-MS/MS for determination of eluxadoline in plasma sample: Application in pharmacokinetic characterization of PLGA nanoparticle formulations in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29121571/),1/[mlmin],0.3,76257,DB00734,Risperidone
,20606310,Volume of distribution,Volume of distribution of topiramate was 0.518 l/kg.,A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20606310/),[l] / [kg],0.518,78908,DB00734,Risperidone
,20606310,oral clearance,"For a typical patient oral clearance was estimated at 1.47 l/h, with interindividual variability of 39.2%.",A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20606310/),[l] / [h],1.47,78909,DB00734,Risperidone
,22632481,Terminal half-life,Terminal half-life is approximately 23 h.,"Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22632481/),h,23,79658,DB00734,Risperidone
,8748391,t1/2,"In addition, the t1/2 of the active moiety was prolonged (19 h in young subjects versus about 25 h in elderly and renal disease patients).","Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8748391/),h,19,81649,DB00734,Risperidone
,8748391,t1/2,"In addition, the t1/2 of the active moiety was prolonged (19 h in young subjects versus about 25 h in elderly and renal disease patients).","Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8748391/),h,25,81650,DB00734,Risperidone
,7520903,half-life,In poor metabolizers the half-life of risperidone was about 19 hours compared with about 3 hours in extensive metabolizers.,The pharmacokinetics of risperidone in humans: a summary. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7520903/),h,19,83624,DB00734,Risperidone
,7520903,half-life,In poor metabolizers the half-life of risperidone was about 19 hours compared with about 3 hours in extensive metabolizers.,The pharmacokinetics of risperidone in humans: a summary. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7520903/),h,3,83625,DB00734,Risperidone
,7520903,half-life,"However, becuase the pharmacology of 9-hydroxyrisperidone is very similar to that of risperidone, the half-life for the ""active fraction"" (risperidone +9-hydroxyrisperidone) was found to be approximately 20 hours in extensive and poor metabolizers.",The pharmacokinetics of risperidone in humans: a summary. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7520903/),h,20,83626,DB00734,Risperidone
,11791898,concentrations/dose (C/Ds),"The median concentrations/dose (C/Ds) (range) of risperidone in CYP2D6*1/*1, *1/*10, and *10/*10 groups were 1.7 (0.2-7.9), 2.6 (0.3-27.1), and 6.7 nM/mg (2.4-21.0), respectively.",Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11791898/),,1.7,84787,DB00734,Risperidone
,11791898,concentrations/dose (C/Ds),"The median concentrations/dose (C/Ds) (range) of risperidone in CYP2D6*1/*1, *1/*10, and *10/*10 groups were 1.7 (0.2-7.9), 2.6 (0.3-27.1), and 6.7 nM/mg (2.4-21.0), respectively.",Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11791898/),[nM] / [mg],2.6,84788,DB00734,Risperidone
,11791898,concentrations/dose (C/Ds),"The median concentrations/dose (C/Ds) (range) of risperidone in CYP2D6*1/*1, *1/*10, and *10/*10 groups were 1.7 (0.2-7.9), 2.6 (0.3-27.1), and 6.7 nM/mg (2.4-21.0), respectively.",Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11791898/),[nM] / [mg],6.7,84789,DB00734,Risperidone
,11791898,C/Ds,"For 9-hydroxyriperidone, the corresponding median C/Ds were 13.1 (3.3-25.4), 11.9 (4.2-30.8), and 13.6 nM/mg (6.5-52.8), respectively, with no significant difference between the genotypes (P=0.54).",Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11791898/),[nM] / [mg],13.1,84790,DB00734,Risperidone
,11791898,C/Ds,"For 9-hydroxyriperidone, the corresponding median C/Ds were 13.1 (3.3-25.4), 11.9 (4.2-30.8), and 13.6 nM/mg (6.5-52.8), respectively, with no significant difference between the genotypes (P=0.54).",Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11791898/),[nM] / [mg],11.9,84791,DB00734,Risperidone
,11791898,C/Ds,"For 9-hydroxyriperidone, the corresponding median C/Ds were 13.1 (3.3-25.4), 11.9 (4.2-30.8), and 13.6 nM/mg (6.5-52.8), respectively, with no significant difference between the genotypes (P=0.54).",Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11791898/),[nM] / [mg],13.6,84792,DB00734,Risperidone
,24491908,receptor occupancy levels,"Estimated dopamine D2 receptor occupancy levels at trough were significantly higher in subjects who developed involuntary movements (N=23) than those who did not (N=195) (71.7±14.4% vs. 64.3±19.3%, p<0.05) while no significant difference was found in the estimated peak D2 receptor occupancy between them (75.4±8.7% vs. 72.1±9.9%, p=0.07).",Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24491908/),%,71.7,88871,DB00734,Risperidone
,24491908,receptor occupancy levels,"Estimated dopamine D2 receptor occupancy levels at trough were significantly higher in subjects who developed involuntary movements (N=23) than those who did not (N=195) (71.7±14.4% vs. 64.3±19.3%, p<0.05) while no significant difference was found in the estimated peak D2 receptor occupancy between them (75.4±8.7% vs. 72.1±9.9%, p=0.07).",Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24491908/),%,64.3,88872,DB00734,Risperidone
,24491908,peak D2 receptor occupancy,"Estimated dopamine D2 receptor occupancy levels at trough were significantly higher in subjects who developed involuntary movements (N=23) than those who did not (N=195) (71.7±14.4% vs. 64.3±19.3%, p<0.05) while no significant difference was found in the estimated peak D2 receptor occupancy between them (75.4±8.7% vs. 72.1±9.9%, p=0.07).",Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24491908/),%,75.4,88873,DB00734,Risperidone
,24491908,peak D2 receptor occupancy,"Estimated dopamine D2 receptor occupancy levels at trough were significantly higher in subjects who developed involuntary movements (N=23) than those who did not (N=195) (71.7±14.4% vs. 64.3±19.3%, p<0.05) while no significant difference was found in the estimated peak D2 receptor occupancy between them (75.4±8.7% vs. 72.1±9.9%, p=0.07).",Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24491908/),%,72.1,88874,DB00734,Risperidone
,11510628,time to reach maximum observed plasma concentration,"In pharmacokinetic studies in humans, quetiapine was rapidly absorbed after oral administration, with median time to reach maximum observed plasma concentration ranging from 1 to 2 hours.",Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510628/),h,1 to 2,91263,DB00734,Risperidone
,11510628,terminal half-life,The drug is eliminated with a mean terminal half-life of approximately 7 hours.,Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510628/),h,7,91264,DB00734,Risperidone
,15018785,flow-rate,"The HPLC separation of the analytes was performed on a MACHEREY-NAGEL C(18) (2.0 mm x 125 mm, 3 microm, Germany) column, using water (formic acid: 2.70 mmol/l, ammonium acetate: 10 mmol/l)-acetonitrile (53:47) as mobile phase, with a flow-rate of 0.16 ml/min.","Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15018785/),[ml] / [min],0.16,91882,DB00734,Risperidone
above,15018785,extraction recoveries,The average extraction recoveries for all the four analysts were at least above 80%.,"Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15018785/),%,80,91883,DB00734,Risperidone
higher,15018785,recoveries,The methodology recoveries were higher than 91% for the analysts.,"Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15018785/),%,91,91884,DB00734,Risperidone
,7545821,receptor,"D2 receptor occupancy was 50% and 54% in the two PM, as compared to 40%, 43% and 55% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,50,92569,DB00734,Risperidone
,7545821,occupancy,"D2 receptor occupancy was 50% and 54% in the two PM, as compared to 40%, 43% and 55% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,50,92570,DB00734,Risperidone
,7545821,occupancy,"D2 receptor occupancy was 50% and 54% in the two PM, as compared to 40%, 43% and 55% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,54,92571,DB00734,Risperidone
,7545821,occupancy,"D2 receptor occupancy was 50% and 54% in the two PM, as compared to 40%, 43% and 55% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,40,92572,DB00734,Risperidone
,7545821,occupancy,"D2 receptor occupancy was 50% and 54% in the two PM, as compared to 40%, 43% and 55% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,43,92573,DB00734,Risperidone
,7545821,occupancy,"D2 receptor occupancy was 50% and 54% in the two PM, as compared to 40%, 43% and 55% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,55,92574,DB00734,Risperidone
,7545821,occupancy,"5-HT2 receptor occupancy was 63% and 73%, as compared to 45%, 56% and 68% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,63,92575,DB00734,Risperidone
,7545821,occupancy,"5-HT2 receptor occupancy was 63% and 73%, as compared to 45%, 56% and 68% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,73,92576,DB00734,Risperidone
,7545821,occupancy,"5-HT2 receptor occupancy was 63% and 73%, as compared to 45%, 56% and 68% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,45,92577,DB00734,Risperidone
,7545821,occupancy,"5-HT2 receptor occupancy was 63% and 73%, as compared to 45%, 56% and 68% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,56,92578,DB00734,Risperidone
,7545821,occupancy,"5-HT2 receptor occupancy was 63% and 73%, as compared to 45%, 56% and 68% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,68,92579,DB00734,Risperidone
,16775814,m/z,The mass transition ion-pair was followed as m/z 411.28 --> 191.15 for RSP and m/z 427.30 --> 207.10 for 9-OH-RSP.,Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16775814/),,411.28,95648,DB00734,Risperidone
,16775814,m/z,The mass transition ion-pair was followed as m/z 411.28 --> 191.15 for RSP and m/z 427.30 --> 207.10 for 9-OH-RSP.,Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16775814/),,191.15,95649,DB00734,Risperidone
,16775814,m/z,The mass transition ion-pair was followed as m/z 411.28 --> 191.15 for RSP and m/z 427.30 --> 207.10 for 9-OH-RSP.,Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16775814/),,427.30,95650,DB00734,Risperidone
,16775814,m/z,The mass transition ion-pair was followed as m/z 411.28 --> 191.15 for RSP and m/z 427.30 --> 207.10 for 9-OH-RSP.,Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16775814/),,207.10,95651,DB00734,Risperidone
,16775814,overall recoveries,"The overall recoveries for RSP and 9-OH-RSP were 82.1% and 83.2%, respectively.",Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16775814/),%,82.1,95652,DB00734,Risperidone
,16775814,overall recoveries,"The overall recoveries for RSP and 9-OH-RSP were 82.1% and 83.2%, respectively.",Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16775814/),%,83.2,95653,DB00734,Risperidone
,16775814,total analysis time,The total analysis time was as low as 3.0 min only.,Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16775814/),min,3.0,95654,DB00734,Risperidone
,10862124,analysis time,The analysis time for each sample was 4 min and more than 100 samples could be analyzed in one day by running the system overnight.,Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10862124/),min,4,97773,DB00734,Risperidone
,17460786,time-to-peak plasma concentration,Its pharmacokinetic profile is characterized by a mean time-to-peak plasma concentration of 24.1 hours and an elimination half-life of approximately 24 hours.,"Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17460786/),h,24.1,98845,DB00734,Risperidone
,17460786,elimination half-life,Its pharmacokinetic profile is characterized by a mean time-to-peak plasma concentration of 24.1 hours and an elimination half-life of approximately 24 hours.,"Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17460786/),h,24,98846,DB00734,Risperidone
,18810393,blood serum concentration,"After administration via drinking water in saline-injected control animals, the hal blood serum concentration was 2.6 +/- 0.45 ng/ml.",Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18810393/),[ng] / [ml],2.6,99177,DB00734,Risperidone
,18810393,serum concentration,"In ket-injected animals, the mean serum concentration of hal amounted to 1.2 +/- 0.44 ng/ml.",Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18810393/),[ng] / [ml],1.2,99178,DB00734,Risperidone
,27416102,mean plasma concentration,"The pharmacokinetic of the active moiety was biphasic for all three dose groups, and the mean plasma concentration was 21.45, 24.60, and 29.68 ng/ml in the 50, 75, and 100 mg group, respectively, 24 h after dose administration; 22.81, 24.57, and 31.41 ng/ml in the 50, 75, and 100 mg group, respectively, 48 h after dose administration, and 12.26, 17.31, and 20.01 ng/ml in the 50, 75, and 100 mg group, respectively, 30 days after dose administration.","Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27416102/),[ng] / [ml],21.45,106381,DB00734,Risperidone
,27416102,mean plasma concentration,"The pharmacokinetic of the active moiety was biphasic for all three dose groups, and the mean plasma concentration was 21.45, 24.60, and 29.68 ng/ml in the 50, 75, and 100 mg group, respectively, 24 h after dose administration; 22.81, 24.57, and 31.41 ng/ml in the 50, 75, and 100 mg group, respectively, 48 h after dose administration, and 12.26, 17.31, and 20.01 ng/ml in the 50, 75, and 100 mg group, respectively, 30 days after dose administration.","Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27416102/),[ng] / [ml],24.60,106382,DB00734,Risperidone
,27416102,mean plasma concentration,"The pharmacokinetic of the active moiety was biphasic for all three dose groups, and the mean plasma concentration was 21.45, 24.60, and 29.68 ng/ml in the 50, 75, and 100 mg group, respectively, 24 h after dose administration; 22.81, 24.57, and 31.41 ng/ml in the 50, 75, and 100 mg group, respectively, 48 h after dose administration, and 12.26, 17.31, and 20.01 ng/ml in the 50, 75, and 100 mg group, respectively, 30 days after dose administration.","Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27416102/),[ng] / [ml],29.68,106383,DB00734,Risperidone
,27416102,mean plasma concentration,"The pharmacokinetic of the active moiety was biphasic for all three dose groups, and the mean plasma concentration was 21.45, 24.60, and 29.68 ng/ml in the 50, 75, and 100 mg group, respectively, 24 h after dose administration; 22.81, 24.57, and 31.41 ng/ml in the 50, 75, and 100 mg group, respectively, 48 h after dose administration, and 12.26, 17.31, and 20.01 ng/ml in the 50, 75, and 100 mg group, respectively, 30 days after dose administration.","Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27416102/),[ng] / [ml],22.81,106384,DB00734,Risperidone
,27416102,mean plasma concentration,"The pharmacokinetic of the active moiety was biphasic for all three dose groups, and the mean plasma concentration was 21.45, 24.60, and 29.68 ng/ml in the 50, 75, and 100 mg group, respectively, 24 h after dose administration; 22.81, 24.57, and 31.41 ng/ml in the 50, 75, and 100 mg group, respectively, 48 h after dose administration, and 12.26, 17.31, and 20.01 ng/ml in the 50, 75, and 100 mg group, respectively, 30 days after dose administration.","Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27416102/),[ng] / [ml],24.57,106385,DB00734,Risperidone
,27416102,mean plasma concentration,"The pharmacokinetic of the active moiety was biphasic for all three dose groups, and the mean plasma concentration was 21.45, 24.60, and 29.68 ng/ml in the 50, 75, and 100 mg group, respectively, 24 h after dose administration; 22.81, 24.57, and 31.41 ng/ml in the 50, 75, and 100 mg group, respectively, 48 h after dose administration, and 12.26, 17.31, and 20.01 ng/ml in the 50, 75, and 100 mg group, respectively, 30 days after dose administration.","Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27416102/),[ng] / [ml],31.41,106386,DB00734,Risperidone
,27416102,mean plasma concentration,"The pharmacokinetic of the active moiety was biphasic for all three dose groups, and the mean plasma concentration was 21.45, 24.60, and 29.68 ng/ml in the 50, 75, and 100 mg group, respectively, 24 h after dose administration; 22.81, 24.57, and 31.41 ng/ml in the 50, 75, and 100 mg group, respectively, 48 h after dose administration, and 12.26, 17.31, and 20.01 ng/ml in the 50, 75, and 100 mg group, respectively, 30 days after dose administration.","Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27416102/),[ng] / [ml],12.26,106387,DB00734,Risperidone
,27416102,mean plasma concentration,"The pharmacokinetic of the active moiety was biphasic for all three dose groups, and the mean plasma concentration was 21.45, 24.60, and 29.68 ng/ml in the 50, 75, and 100 mg group, respectively, 24 h after dose administration; 22.81, 24.57, and 31.41 ng/ml in the 50, 75, and 100 mg group, respectively, 48 h after dose administration, and 12.26, 17.31, and 20.01 ng/ml in the 50, 75, and 100 mg group, respectively, 30 days after dose administration.","Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27416102/),[ng] / [ml],17.31,106388,DB00734,Risperidone
,27416102,mean plasma concentration,"The pharmacokinetic of the active moiety was biphasic for all three dose groups, and the mean plasma concentration was 21.45, 24.60, and 29.68 ng/ml in the 50, 75, and 100 mg group, respectively, 24 h after dose administration; 22.81, 24.57, and 31.41 ng/ml in the 50, 75, and 100 mg group, respectively, 48 h after dose administration, and 12.26, 17.31, and 20.01 ng/ml in the 50, 75, and 100 mg group, respectively, 30 days after dose administration.","Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27416102/),[ng] / [ml],20.01,106389,DB00734,Risperidone
,7531352,apparent elimination half-life,"In plasma, the apparent elimination half-life of risperidone was 1.0 h, and mean residence times were 1.5 h for risperidone and 2.5 h for its 9-hydroxy metabolite.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,1.0,108472,DB00734,Risperidone
,7531352,mean residence times,"In plasma, the apparent elimination half-life of risperidone was 1.0 h, and mean residence times were 1.5 h for risperidone and 2.5 h for its 9-hydroxy metabolite.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,1.5,108473,DB00734,Risperidone
,7531352,mean residence times,"In plasma, the apparent elimination half-life of risperidone was 1.0 h, and mean residence times were 1.5 h for risperidone and 2.5 h for its 9-hydroxy metabolite.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,2.5,108474,DB00734,Risperidone
,7531352,half-lives,"After a subcutaneous dose of 0.02 mg/kg, the ED50 for central 5-HT2 antagonism in male rats, half-lives in frontal cortex and striatum were 3-4 h for risperidone, whereas mean residence times were 4-6 h for risperidone and about 12 h for 9-hydroxy-risperidone.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,3-4,108475,DB00734,Risperidone
,7531352,mean residence times,"After a subcutaneous dose of 0.02 mg/kg, the ED50 for central 5-HT2 antagonism in male rats, half-lives in frontal cortex and striatum were 3-4 h for risperidone, whereas mean residence times were 4-6 h for risperidone and about 12 h for 9-hydroxy-risperidone.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,4-6,108476,DB00734,Risperidone
,7531352,mean residence times,"After a subcutaneous dose of 0.02 mg/kg, the ED50 for central 5-HT2 antagonism in male rats, half-lives in frontal cortex and striatum were 3-4 h for risperidone, whereas mean residence times were 4-6 h for risperidone and about 12 h for 9-hydroxy-risperidone.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,12,108477,DB00734,Risperidone
,32116683,absorption percentage,"The predicted absorption percentage via oral mucosa at oral residence time of 2 min, 5 min, and 10 min was 7.0%, 11.4%, and 19.5%, respectively.",Physiologically Based Pharmacokinetic Modeling to Understand the Absorption of Risperidone Orodispersible Film. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116683/),%,7.0,109471,DB00734,Risperidone
,32116683,absorption percentage,"The predicted absorption percentage via oral mucosa at oral residence time of 2 min, 5 min, and 10 min was 7.0%, 11.4%, and 19.5%, respectively.",Physiologically Based Pharmacokinetic Modeling to Understand the Absorption of Risperidone Orodispersible Film. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116683/),%,11.4,109472,DB00734,Risperidone
,32116683,absorption percentage,"The predicted absorption percentage via oral mucosa at oral residence time of 2 min, 5 min, and 10 min was 7.0%, 11.4%, and 19.5%, respectively.",Physiologically Based Pharmacokinetic Modeling to Understand the Absorption of Risperidone Orodispersible Film. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116683/),%,19.5,109473,DB00734,Risperidone
,11076069,flow-rate,"The mobile phase consisted of phosphate buffer (0.05 M, pH 3.7 with 25% H3PO4)-acetonitrile (70:30, v/v), and was delivered at a flow-rate of 1.0 ml/min.",Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11076069/),[ml] / [min],1.0,111533,DB00734,Risperidone
,11076069,total time,The peaks were detected using a UV detector set at 278 nm and the total time for a chromatographic separation was about 4 min.,Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11076069/),min,4,111534,DB00734,Risperidone
,11076069,recoveries,Mean recoveries were 98.0% for risperidone and 83.5% for 9-hydroxyrisperidone.,Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11076069/),%,98.0,111535,DB00734,Risperidone
,11076069,recoveries,Mean recoveries were 98.0% for risperidone and 83.5% for 9-hydroxyrisperidone.,Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11076069/),%,83.5,111536,DB00734,Risperidone
,11985287,AUC,"The mean (+/- SD) AUC of risperidone increased from 83.1 +/- 46.8 ng.h/ml and 398.3 +/- 33.2 ng.h/ml (monotherapy) to 345.1 +/- 158.0 ng.h/ml (p < 0.05) and 514.0 +/- 144.2 ng.h/ml (p < 0.001) when coadministered with fluoxetine in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],83.1,116345,DB00734,Risperidone
,11985287,AUC,"The mean (+/- SD) AUC of risperidone increased from 83.1 +/- 46.8 ng.h/ml and 398.3 +/- 33.2 ng.h/ml (monotherapy) to 345.1 +/- 158.0 ng.h/ml (p < 0.05) and 514.0 +/- 144.2 ng.h/ml (p < 0.001) when coadministered with fluoxetine in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],398.3,116346,DB00734,Risperidone
,11985287,AUC,"The mean (+/- SD) AUC of risperidone increased from 83.1 +/- 46.8 ng.h/ml and 398.3 +/- 33.2 ng.h/ml (monotherapy) to 345.1 +/- 158.0 ng.h/ml (p < 0.05) and 514.0 +/- 144.2 ng.h/ml (p < 0.001) when coadministered with fluoxetine in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],345.1,116347,DB00734,Risperidone
,11985287,AUC,"The mean (+/- SD) AUC of risperidone increased from 83.1 +/- 46.8 ng.h/ml and 398.3 +/- 33.2 ng.h/ml (monotherapy) to 345.1 +/- 158.0 ng.h/ml (p < 0.05) and 514.0 +/- 144.2 ng.h/ml (p < 0.001) when coadministered with fluoxetine in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],514.0,116348,DB00734,Risperidone
,11985287,AUC,"The AUC of the active moiety (risperidone plus 9-hydroxy-risperidone) increased from 470.0 +/- 170.0 ng.h/ml to 663.0 +/- 243.3 ng.h/ml (p < 0.05)and from 576.3 +/- 19.6 ng.h/ml to 788.0 +/- 89.1 ng.h/ml (ns) in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],470.0,116349,DB00734,Risperidone
,11985287,AUC,"The AUC of the active moiety (risperidone plus 9-hydroxy-risperidone) increased from 470.0 +/- 170.0 ng.h/ml to 663.0 +/- 243.3 ng.h/ml (p < 0.05)and from 576.3 +/- 19.6 ng.h/ml to 788.0 +/- 89.1 ng.h/ml (ns) in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],663.0,116350,DB00734,Risperidone
,11985287,AUC,"The AUC of the active moiety (risperidone plus 9-hydroxy-risperidone) increased from 470.0 +/- 170.0 ng.h/ml to 663.0 +/- 243.3 ng.h/ml (p < 0.05)and from 576.3 +/- 19.6 ng.h/ml to 788.0 +/- 89.1 ng.h/ml (ns) in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],576.3,116351,DB00734,Risperidone
,11985287,AUC,"The AUC of the active moiety (risperidone plus 9-hydroxy-risperidone) increased from 470.0 +/- 170.0 ng.h/ml to 663.0 +/- 243.3 ng.h/ml (p < 0.05)and from 576.3 +/- 19.6 ng.h/ml to 788.0 +/- 89.1 ng.h/ml (ns) in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],788.0,116352,DB00734,Risperidone
,11985287,AUC,"In EMs, the AUC of 9-hydroxy-risperidone remained similar (monotherapy vs. combination therapy: 386.8 +/- 153.0 ng.h/ml vs. 317.7 +/- 125.2 ng.h/ml, ns),whereas it increased in PMs (178.3 +/- 23.5 ng.h/ml vs. 274.0 +/- 55.1 ng.h/ml (p < 0.05)).",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],386.8,116353,DB00734,Risperidone
,11985287,AUC,"In EMs, the AUC of 9-hydroxy-risperidone remained similar (monotherapy vs. combination therapy: 386.8 +/- 153.0 ng.h/ml vs. 317.7 +/- 125.2 ng.h/ml, ns),whereas it increased in PMs (178.3 +/- 23.5 ng.h/ml vs. 274.0 +/- 55.1 ng.h/ml (p < 0.05)).",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],317.7,116354,DB00734,Risperidone
,11985287,AUC,"In EMs, the AUC of 9-hydroxy-risperidone remained similar (monotherapy vs. combination therapy: 386.8 +/- 153.0 ng.h/ml vs. 317.7 +/- 125.2 ng.h/ml, ns),whereas it increased in PMs (178.3 +/- 23.5 ng.h/ml vs. 274.0 +/- 55.1 ng.h/ml (p < 0.05)).",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],178.3,116355,DB00734,Risperidone
,11985287,AUC,"In EMs, the AUC of 9-hydroxy-risperidone remained similar (monotherapy vs. combination therapy: 386.8 +/- 153.0 ng.h/ml vs. 317.7 +/- 125.2 ng.h/ml, ns),whereas it increased in PMs (178.3 +/- 23.5 ng.h/ml vs. 274.0 +/- 55.1 ng.h/ml (p < 0.05)).",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],274.0,116356,DB00734,Risperidone
below,16195099,total serum drug levels,"About 25% of patients receiving risperidone depot showed total serum drug levels below established reference range (30-120 nmol/l), even when steady state was presumed.",Therapeutic drug monitoring of patients on risperidone depot. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16195099/),[nM] / [l],30-120,120411,DB00734,Risperidone
,20683501,half-life,"After intramuscular injection, paliperidone palmitate is slowly hydrolyzed to paliperidone with a mean half-life of 24-49 days, depending on the dose.","Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20683501/),d,24-49,128805,DB00734,Risperidone
,28165818,bioavailability,"The drug bioavailability was significantly increased in comparison to the conventional tablets (1441.711 μg h/mL and 137.518 μg/mL in comparison to 321.011 μg h/mL and 38.673 μg/mL for AUC and Cpmax, respectively).",Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28165818/),[h·μg] / [ml],1441.711,130599,DB00734,Risperidone
,28165818,bioavailability,"The drug bioavailability was significantly increased in comparison to the conventional tablets (1441.711 μg h/mL and 137.518 μg/mL in comparison to 321.011 μg h/mL and 38.673 μg/mL for AUC and Cpmax, respectively).",Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28165818/),[μg] / [ml],137.518,130600,DB00734,Risperidone
,28165818,bioavailability,"The drug bioavailability was significantly increased in comparison to the conventional tablets (1441.711 μg h/mL and 137.518 μg/mL in comparison to 321.011 μg h/mL and 38.673 μg/mL for AUC and Cpmax, respectively).",Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28165818/),[h·μg] / [ml],321.011,130601,DB00734,Risperidone
,28165818,bioavailability,"The drug bioavailability was significantly increased in comparison to the conventional tablets (1441.711 μg h/mL and 137.518 μg/mL in comparison to 321.011 μg h/mL and 38.673 μg/mL for AUC and Cpmax, respectively).",Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28165818/),[μg] / [ml],38.673,130602,DB00734,Risperidone
,28165818,AUC,"The drug bioavailability was significantly increased in comparison to the conventional tablets (1441.711 μg h/mL and 137.518 μg/mL in comparison to 321.011 μg h/mL and 38.673 μg/mL for AUC and Cpmax, respectively).",Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28165818/),[h·μg] / [ml],321.011,130603,DB00734,Risperidone
,28165818,AUC,"The drug bioavailability was significantly increased in comparison to the conventional tablets (1441.711 μg h/mL and 137.518 μg/mL in comparison to 321.011 μg h/mL and 38.673 μg/mL for AUC and Cpmax, respectively).",Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28165818/),[μg] / [ml],38.673,130604,DB00734,Risperidone
,28165818,Cpmax,"The drug bioavailability was significantly increased in comparison to the conventional tablets (1441.711 μg h/mL and 137.518 μg/mL in comparison to 321.011 μg h/mL and 38.673 μg/mL for AUC and Cpmax, respectively).",Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28165818/),[μg] / [ml],38.673,130605,DB00734,Risperidone
,16460829,oral bioavailability,The oral bioavailability of the polymer was 40%.,Intestinal uptake and biodistribution of novel polymeric micelles after oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16460829/),%,40,131555,DB00734,Risperidone
,31094571,zeta potential,"Results: Risperidone nanoparticles (RP12) were produced with an average size of 86 nm, polydispersity index of 0.287, zeta potential of +36.6 mV, mucoadhesion of 68.9% and entrapment efficiency of 77.96%.",Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094571/),mv,+,131619,DB00734,Risperidone
,31094571,zeta potential,"Results: Risperidone nanoparticles (RP12) were produced with an average size of 86 nm, polydispersity index of 0.287, zeta potential of +36.6 mV, mucoadhesion of 68.9% and entrapment efficiency of 77.96%.",Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094571/),mv,36.6,131620,DB00734,Risperidone
,31094571,mucoadhesion,"Results: Risperidone nanoparticles (RP12) were produced with an average size of 86 nm, polydispersity index of 0.287, zeta potential of +36.6 mV, mucoadhesion of 68.9% and entrapment efficiency of 77.96%.",Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094571/),%,68.9,131621,DB00734,Risperidone
,31094571,entrapment efficiency,"Results: Risperidone nanoparticles (RP12) were produced with an average size of 86 nm, polydispersity index of 0.287, zeta potential of +36.6 mV, mucoadhesion of 68.9% and entrapment efficiency of 77.96%.",Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094571/),%,77.96,131622,DB00734,Risperidone
,31094571,Maximum concentration,"Maximum concentration of RS in plasma was 1240 ng/ml at 4 h for RP12, and 403.8 ng/ml at 2 h for RS sample.",Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094571/),[ng] / [ml],1240,131623,DB00734,Risperidone
,31094571,Maximum concentration,"Maximum concentration of RS in plasma was 1240 ng/ml at 4 h for RP12, and 403.8 ng/ml at 2 h for RS sample.",Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094571/),[ng] / [ml],403.8,131624,DB00734,Risperidone
,16598965,peak plasma level,"The most interesting results, obtained at steady-state, were a lower predicted peak plasma level (46 vs. 62 ng/ml) and a lower predicted degree of fluctuation between Cssmax and Cssmin (53 vs 145%) with LAI compared to oral administration, which is in line with actual steady state data on LAI risperidone.",Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16598965/),[ng] / [ml],46,134087,DB00734,Risperidone
,16598965,peak plasma level,"The most interesting results, obtained at steady-state, were a lower predicted peak plasma level (46 vs. 62 ng/ml) and a lower predicted degree of fluctuation between Cssmax and Cssmin (53 vs 145%) with LAI compared to oral administration, which is in line with actual steady state data on LAI risperidone.",Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16598965/),[ng] / [ml],62,134088,DB00734,Risperidone
,14764214,half-life,Mean half-life of dopamine D2 receptor occupancy of risperidone was 80.2 h while that of the plasma concentration was 17.8 h.,Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14764214/),h,80.2,134555,DB00734,Risperidone
,14764214,half-life,Mean half-life of dopamine D2 receptor occupancy of risperidone was 80.2 h while that of the plasma concentration was 17.8 h.,Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14764214/),h,17.8,134556,DB00734,Risperidone
,14764214,half-life of receptor occupancy,"When the ED50 value was changed to one-tenth and 10-fold, the simulated half-life of receptor occupancy changed to 117.6 h and 27.3 h respectively.",Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14764214/),h,117.6,134557,DB00734,Risperidone
,14764214,half-life of receptor occupancy,"When the ED50 value was changed to one-tenth and 10-fold, the simulated half-life of receptor occupancy changed to 117.6 h and 27.3 h respectively.",Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14764214/),h,27.3,134558,DB00734,Risperidone
,26387027,maximum plasma concentration (C max),Risperidone maximum plasma concentration (C max) decreased from mean 16.5 ng/mL when given alone to 9.2 ng/mL after armodafinil pretreatment (geometric mean ratio [90 % CI] 0.55 [0.50-0.61]); area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞) decreased from 92.3 to 44.5 ng·h/mL (geometric mean ratio [90 % CI] 0.51 [0.46-0.55]).,Evaluation of potential pharmacokinetic drug-drug interaction between armodafinil and risperidone in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26387027/),[ng] / [ml],16.5,135343,DB00734,Risperidone
,26387027,maximum plasma concentration (C max),Risperidone maximum plasma concentration (C max) decreased from mean 16.5 ng/mL when given alone to 9.2 ng/mL after armodafinil pretreatment (geometric mean ratio [90 % CI] 0.55 [0.50-0.61]); area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞) decreased from 92.3 to 44.5 ng·h/mL (geometric mean ratio [90 % CI] 0.51 [0.46-0.55]).,Evaluation of potential pharmacokinetic drug-drug interaction between armodafinil and risperidone in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26387027/),[ng] / [ml],9.2,135344,DB00734,Risperidone
,26387027,area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞),Risperidone maximum plasma concentration (C max) decreased from mean 16.5 ng/mL when given alone to 9.2 ng/mL after armodafinil pretreatment (geometric mean ratio [90 % CI] 0.55 [0.50-0.61]); area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞) decreased from 92.3 to 44.5 ng·h/mL (geometric mean ratio [90 % CI] 0.51 [0.46-0.55]).,Evaluation of potential pharmacokinetic drug-drug interaction between armodafinil and risperidone in healthy adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26387027/),[h·ng] / [ml],92.3,135345,DB00734,Risperidone
,26387027,area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞),Risperidone maximum plasma concentration (C max) decreased from mean 16.5 ng/mL when given alone to 9.2 ng/mL after armodafinil pretreatment (geometric mean ratio [90 % CI] 0.55 [0.50-0.61]); area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞) decreased from 92.3 to 44.5 ng·h/mL (geometric mean ratio [90 % CI] 0.51 [0.46-0.55]).,Evaluation of potential pharmacokinetic drug-drug interaction between armodafinil and risperidone in healthy adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26387027/),[h·ng] / [ml],44,135346,DB00734,Risperidone
,19457210,serum concentration,"The mean serum concentration of risperidone plus 9-hydroxyrisperidone was 29.1 ng/mL at the 12th week after switching, with an average injection dose of 31.25 mg long-acting risperidone every two weeks.",Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19457210/),[ng] / [ml],29.1,136521,DB00734,Risperidone
,19825908,C(max),"Mean serum prolactin concentrations increased on day 1 (C(max): 71.8 ng/ml and 89.7 ng/ml reached at 6.5 hours and 2.6 hours for paliperidone extended-release and risperidone immediate-release, respectively).",A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825908/),[ng] / [ml],71.8,139011,DB00734,Risperidone
,19825908,C(max),"Mean serum prolactin concentrations increased on day 1 (C(max): 71.8 ng/ml and 89.7 ng/ml reached at 6.5 hours and 2.6 hours for paliperidone extended-release and risperidone immediate-release, respectively).",A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825908/),[ng] / [ml],89.7,139012,DB00734,Risperidone
,19825908,AUC(0-24 h),"On day 6, serum prolactin concentration-time profiles were similar for both treatments, with overall higher serum prolactin concentrations than on day 1 (AUC(0-24 h): 1389 and 842 ng h/ml, and 1306 and 741 ng.h/ml on day 6 and day 1 for paliperidone extended-release and risperidone immediate-release, respectively).",A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825908/),[h·ng] / [ml],1389,139013,DB00734,Risperidone
,19825908,AUC(0-24 h),"On day 6, serum prolactin concentration-time profiles were similar for both treatments, with overall higher serum prolactin concentrations than on day 1 (AUC(0-24 h): 1389 and 842 ng h/ml, and 1306 and 741 ng.h/ml on day 6 and day 1 for paliperidone extended-release and risperidone immediate-release, respectively).",A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825908/),[h·ng] / [ml],842,139014,DB00734,Risperidone
,19825908,AUC(0-24 h),"On day 6, serum prolactin concentration-time profiles were similar for both treatments, with overall higher serum prolactin concentrations than on day 1 (AUC(0-24 h): 1389 and 842 ng h/ml, and 1306 and 741 ng.h/ml on day 6 and day 1 for paliperidone extended-release and risperidone immediate-release, respectively).",A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825908/),[h·ng] / [ml],1306,139015,DB00734,Risperidone
,19825908,AUC(0-24 h),"On day 6, serum prolactin concentration-time profiles were similar for both treatments, with overall higher serum prolactin concentrations than on day 1 (AUC(0-24 h): 1389 and 842 ng h/ml, and 1306 and 741 ng.h/ml on day 6 and day 1 for paliperidone extended-release and risperidone immediate-release, respectively).",A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825908/),[h·ng] / [ml],741,139016,DB00734,Risperidone
,21194608,relative bioavailabilities,"The mean (SD) relative bioavailabilities of test to reference formulations determined from AUC of the active moiety, risperidone, and 9-hydroxyrisperidone were 1.06 (0.18), 1.07 (0.29), and 1.04 (0.17), respectively.","Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: A single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in Thailand. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194608/),,1.06,139294,DB00734,Risperidone
,21194608,relative bioavailabilities,"The mean (SD) relative bioavailabilities of test to reference formulations determined from AUC of the active moiety, risperidone, and 9-hydroxyrisperidone were 1.06 (0.18), 1.07 (0.29), and 1.04 (0.17), respectively.","Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: A single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in Thailand. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194608/),,1.07,139295,DB00734,Risperidone
,21194608,relative bioavailabilities,"The mean (SD) relative bioavailabilities of test to reference formulations determined from AUC of the active moiety, risperidone, and 9-hydroxyrisperidone were 1.06 (0.18), 1.07 (0.29), and 1.04 (0.17), respectively.","Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: A single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in Thailand. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194608/),,1.04,139296,DB00734,Risperidone
,16513859,occupancy,"Mean post- and preinjection D(2) occupancy levels for the 25-, 50-, and 75-mg doses were 71.0% and 54.0%, 74.4% and 65.4%, and 81.5% and 75.0%, respectively.",A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513859/),%,71.0,140211,DB00734,Risperidone
,16513859,occupancy,"Mean post- and preinjection D(2) occupancy levels for the 25-, 50-, and 75-mg doses were 71.0% and 54.0%, 74.4% and 65.4%, and 81.5% and 75.0%, respectively.",A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513859/),%,54.0,140212,DB00734,Risperidone
,16513859,occupancy,"Mean post- and preinjection D(2) occupancy levels for the 25-, 50-, and 75-mg doses were 71.0% and 54.0%, 74.4% and 65.4%, and 81.5% and 75.0%, respectively.",A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513859/),%,74.4,140213,DB00734,Risperidone
,16513859,occupancy,"Mean post- and preinjection D(2) occupancy levels for the 25-, 50-, and 75-mg doses were 71.0% and 54.0%, 74.4% and 65.4%, and 81.5% and 75.0%, respectively.",A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513859/),%,65.4,140214,DB00734,Risperidone
,16513859,occupancy,"Mean post- and preinjection D(2) occupancy levels for the 25-, 50-, and 75-mg doses were 71.0% and 54.0%, 74.4% and 65.4%, and 81.5% and 75.0%, respectively.",A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513859/),%,81.5,140215,DB00734,Risperidone
,16513859,occupancy,"Mean post- and preinjection D(2) occupancy levels for the 25-, 50-, and 75-mg doses were 71.0% and 54.0%, 74.4% and 65.4%, and 81.5% and 75.0%, respectively.",A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513859/),%,75.0,140216,DB00734,Risperidone
,30449206,concentration/dose (C/D) ratio,Using the paliperidone concentration/dose (C/D) ratio as a measure of clearance provided a weighted mean of 7.7 ng/ml per mg/day among 69 patients from three steady-state PP1M studies (twice as high as oral paliperidone).,A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30449206/),[ng] / [d·mg·ml],7.7,141549,DB00734,Risperidone
,30449206,clearance,Using the paliperidone concentration/dose (C/D) ratio as a measure of clearance provided a weighted mean of 7.7 ng/ml per mg/day among 69 patients from three steady-state PP1M studies (twice as high as oral paliperidone).,A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30449206/),[ng] / [d·mg·ml],7.7,141550,DB00734,Risperidone
,12369274,stabilized concentrations,"The therapeutic drug monitoring needed oral Risp daily dose of 4.5 +/- 2.3 mg (range 2-8) and the stabilized concentrations (ng/ml) at endpoint in plasma and RBC were 10 +/- 8 (range 1-23) and 3.5 +/- 2 (range 1-8) for Risp and 29 +/- 19 (range 8-70) and 11.5 +/- 6.6 (range 2.6-22.5) for 9-OH-Risp, respectively.","Long-term pharmacoclinical follow-up in schizophrenic patients treated with risperidone. Plasma and red blood cell concentrations of risperidone and its 9-hydroxymetabolite and their relationship to whole blood serotonin and tryptophan, plasma homovanillic acid, 5-hydroxyindoleacetic acid, dihydroxyphenylethyleneglycol and clinical evaluations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369274/),[ng] / [ml],10,143199,DB00734,Risperidone
,12369274,stabilized concentrations,"The therapeutic drug monitoring needed oral Risp daily dose of 4.5 +/- 2.3 mg (range 2-8) and the stabilized concentrations (ng/ml) at endpoint in plasma and RBC were 10 +/- 8 (range 1-23) and 3.5 +/- 2 (range 1-8) for Risp and 29 +/- 19 (range 8-70) and 11.5 +/- 6.6 (range 2.6-22.5) for 9-OH-Risp, respectively.","Long-term pharmacoclinical follow-up in schizophrenic patients treated with risperidone. Plasma and red blood cell concentrations of risperidone and its 9-hydroxymetabolite and their relationship to whole blood serotonin and tryptophan, plasma homovanillic acid, 5-hydroxyindoleacetic acid, dihydroxyphenylethyleneglycol and clinical evaluations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369274/),[ng] / [ml],3.5,143200,DB00734,Risperidone
,12369274,stabilized concentrations,"The therapeutic drug monitoring needed oral Risp daily dose of 4.5 +/- 2.3 mg (range 2-8) and the stabilized concentrations (ng/ml) at endpoint in plasma and RBC were 10 +/- 8 (range 1-23) and 3.5 +/- 2 (range 1-8) for Risp and 29 +/- 19 (range 8-70) and 11.5 +/- 6.6 (range 2.6-22.5) for 9-OH-Risp, respectively.","Long-term pharmacoclinical follow-up in schizophrenic patients treated with risperidone. Plasma and red blood cell concentrations of risperidone and its 9-hydroxymetabolite and their relationship to whole blood serotonin and tryptophan, plasma homovanillic acid, 5-hydroxyindoleacetic acid, dihydroxyphenylethyleneglycol and clinical evaluations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369274/),[ng] / [ml],29,143201,DB00734,Risperidone
,12369274,stabilized concentrations,"The therapeutic drug monitoring needed oral Risp daily dose of 4.5 +/- 2.3 mg (range 2-8) and the stabilized concentrations (ng/ml) at endpoint in plasma and RBC were 10 +/- 8 (range 1-23) and 3.5 +/- 2 (range 1-8) for Risp and 29 +/- 19 (range 8-70) and 11.5 +/- 6.6 (range 2.6-22.5) for 9-OH-Risp, respectively.","Long-term pharmacoclinical follow-up in schizophrenic patients treated with risperidone. Plasma and red blood cell concentrations of risperidone and its 9-hydroxymetabolite and their relationship to whole blood serotonin and tryptophan, plasma homovanillic acid, 5-hydroxyindoleacetic acid, dihydroxyphenylethyleneglycol and clinical evaluations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369274/),[ng] / [ml],11.5,143202,DB00734,Risperidone
,12450541,recoveries,"The mean recoveries of risperidone and 9-hydroxyrisperidone added to plasma were 96.8 and 99.4%, with an intra-day coefficient of variation of under 5 and 6%, respectively.",Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12450541/),%,96.8,147712,DB00734,Risperidone
,12450541,recoveries,"The mean recoveries of risperidone and 9-hydroxyrisperidone added to plasma were 96.8 and 99.4%, with an intra-day coefficient of variation of under 5 and 6%, respectively.",Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12450541/),%,99.4,147713,DB00734,Risperidone
,26129833,flow rate,The analytes were chromatographed on a Waters Acquity H class UPLC system using isocratic mobile phase conditions at a flow rate of 0.3 mL/min and Acquity UPLC BEH shield RP18 column maintained at 40°C.,"Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),[ml] / [min],0.3,153465,DB00734,Risperidone
,26129833,retention times,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,0.9,153466,DB00734,Risperidone
,26129833,retention times,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,1.4,153467,DB00734,Risperidone
,26129833,retention times,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,.,153468,DB00734,Risperidone
,26129833,retention times,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,1.8,153469,DB00734,Risperidone
,26129833,retention times,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,3.1,153470,DB00734,Risperidone
,26129833,total run time,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,4,153471,DB00734,Risperidone
,27568868,Z-average,"The Z-average and polydispersity Index of developed formulation was 83.1 nm and 0.306, respectively.",Enhanced oral delivery of risperidone through a novel self-nanoemulsifying powder (SNEP) formulations: in-vitro and ex-vivo assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27568868/),nm,83.1,169873,DB00734,Risperidone
,27568868,polydispersity Index,"The Z-average and polydispersity Index of developed formulation was 83.1 nm and 0.306, respectively.",Enhanced oral delivery of risperidone through a novel self-nanoemulsifying powder (SNEP) formulations: in-vitro and ex-vivo assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27568868/),,0.306,169874,DB00734,Risperidone
,16490177,Tmax,Risperidone was rapidly absorbed (Tmax was 1.6 h) and its T1/2 in plasma was short (3.2 h).,Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490177/),h,1.6,172573,DB00734,Risperidone
,16490177,T1/2,Risperidone was rapidly absorbed (Tmax was 1.6 h) and its T1/2 in plasma was short (3.2 h).,Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490177/),h,3.2,172574,DB00734,Risperidone
,16490177,Tmax,9-hydroxy-risperidone was quickly metabolized from the parent drug with a mean Tmax of 2.5 h.,Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490177/),h,2.5,172575,DB00734,Risperidone
,16490177,half-life,It had a long half-life of 24.7 h.,Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490177/),h,24.7,172576,DB00734,Risperidone
,16490177,C(ss)(av),"The C(ss)(av) of risperidone and 9-hydroxy-risperidone were 36.9+/-33.1 and 110.6+/-30.5 microg x h x L(-1), respectively, and the AUC(ss)0-12 were 443.2+/- 397.4 and 1327.2+/- 402.3 microg x h x L(-1), respectively.",Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490177/),[h·μg] / [l],36.9,172577,DB00734,Risperidone
,16490177,C(ss)(av),"The C(ss)(av) of risperidone and 9-hydroxy-risperidone were 36.9+/-33.1 and 110.6+/-30.5 microg x h x L(-1), respectively, and the AUC(ss)0-12 were 443.2+/- 397.4 and 1327.2+/- 402.3 microg x h x L(-1), respectively.",Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490177/),[h·μg] / [l],110.6,172578,DB00734,Risperidone
,16490177,AUC(ss)0-12,"The C(ss)(av) of risperidone and 9-hydroxy-risperidone were 36.9+/-33.1 and 110.6+/-30.5 microg x h x L(-1), respectively, and the AUC(ss)0-12 were 443.2+/- 397.4 and 1327.2+/- 402.3 microg x h x L(-1), respectively.",Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490177/),[h·μg] / [l],443.2,172579,DB00734,Risperidone
,16490177,AUC(ss)0-12,"The C(ss)(av) of risperidone and 9-hydroxy-risperidone were 36.9+/-33.1 and 110.6+/-30.5 microg x h x L(-1), respectively, and the AUC(ss)0-12 were 443.2+/- 397.4 and 1327.2+/- 402.3 microg x h x L(-1), respectively.",Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490177/),[h·μg] / [l],1327.2,172580,DB00734,Risperidone
,16490177,CL/F,"CL/F and V/F of risperidone were 8.7+/- 6.2 L/h and 34.1+/- 24.3 L, respectively.",Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490177/),[l] / [h],8.7,172581,DB00734,Risperidone
,16490177,V/F,"CL/F and V/F of risperidone were 8.7+/- 6.2 L/h and 34.1+/- 24.3 L, respectively.",Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490177/),l,34.1,172582,DB00734,Risperidone
,28733244,bioavailability,Risperidone bioavailability is 66% in extensive metabolizers and 82% in slow metabolizers.,"Response surface optimization, Ex vivo and In vivo investigation of nasal spanlastics for bioavailability enhancement and brain targeting of risperidone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28733244/),%,66,179348,DB00734,Risperidone
,28733244,bioavailability,Risperidone bioavailability is 66% in extensive metabolizers and 82% in slow metabolizers.,"Response surface optimization, Ex vivo and In vivo investigation of nasal spanlastics for bioavailability enhancement and brain targeting of risperidone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28733244/),%,82,179349,DB00734,Risperidone
,7690693,area under the concentration-time curve from time zero to infinity ratio,The plasma area under the concentration-time curve from time zero to infinity ratio of 9-hydroxyrisperidone to risperidone averaged 3 (intravenous and intramuscular) and 6 (oral administration) in the extensive metabolizers and 0.2 in the poor metabolizers.,Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690693/),,3,196714,DB00734,Risperidone
,7690693,area under the concentration-time curve from time zero to infinity ratio,The plasma area under the concentration-time curve from time zero to infinity ratio of 9-hydroxyrisperidone to risperidone averaged 3 (intravenous and intramuscular) and 6 (oral administration) in the extensive metabolizers and 0.2 in the poor metabolizers.,Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690693/),,6,196715,DB00734,Risperidone
,7690693,area under the concentration-time curve from time zero to infinity ratio,The plasma area under the concentration-time curve from time zero to infinity ratio of 9-hydroxyrisperidone to risperidone averaged 3 (intravenous and intramuscular) and 6 (oral administration) in the extensive metabolizers and 0.2 in the poor metabolizers.,Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690693/),,0.2,196716,DB00734,Risperidone
,7690693,half-life,Risperidone half-life was about 3 hours in extensive metabolizers and 22 hours in poor metabolizers.,Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690693/),h,3,196717,DB00734,Risperidone
,7690693,half-life,Risperidone half-life was about 3 hours in extensive metabolizers and 22 hours in poor metabolizers.,Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690693/),h,22,196718,DB00734,Risperidone
,7690693,absolute oral bioavailability,Risperidone absolute oral bioavailability was 66%.,Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690693/),%,66,196719,DB00734,Risperidone
,7690693,terminal half-life,"The pharmacokinetics of the active moiety (risperidone plus 9-hydroxyrisperidone) varied little among subjects (mean terminal half-life, 20 +/- 2 1/2 hours; absolute oral and intramuscular bioavailability, 100%).",Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690693/),h,20,196720,DB00734,Risperidone
,7690693,absolute oral,"The pharmacokinetics of the active moiety (risperidone plus 9-hydroxyrisperidone) varied little among subjects (mean terminal half-life, 20 +/- 2 1/2 hours; absolute oral and intramuscular bioavailability, 100%).",Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690693/),%,100,196721,DB00734,Risperidone
,7690693,intramuscular bioavailability,"The pharmacokinetics of the active moiety (risperidone plus 9-hydroxyrisperidone) varied little among subjects (mean terminal half-life, 20 +/- 2 1/2 hours; absolute oral and intramuscular bioavailability, 100%).",Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690693/),%,100,196722,DB00734,Risperidone
,18308793,D,"Observed striatal D(2)RO and C(P) ranges were 28-75% and 9.4-60.5 ng/mL for risperidone, 22-84% and 8.6-89.5 ng/mL for olanzapine, 5-53% and 41.6-818.2 ng/mL for clozapine and 0-64% and 37.9-719.6 ng/mL for quetiapine.",Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308793/),%,28-75,202598,DB00734,Risperidone
,18308793,RO,"Observed striatal D(2)RO and C(P) ranges were 28-75% and 9.4-60.5 ng/mL for risperidone, 22-84% and 8.6-89.5 ng/mL for olanzapine, 5-53% and 41.6-818.2 ng/mL for clozapine and 0-64% and 37.9-719.6 ng/mL for quetiapine.",Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308793/),%,28-75,202599,DB00734,Risperidone
,18308793,C(P),"Observed striatal D(2)RO and C(P) ranges were 28-75% and 9.4-60.5 ng/mL for risperidone, 22-84% and 8.6-89.5 ng/mL for olanzapine, 5-53% and 41.6-818.2 ng/mL for clozapine and 0-64% and 37.9-719.6 ng/mL for quetiapine.",Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308793/),[ng] / [ml],9.4-60.5,202600,DB00734,Risperidone
,33176899,elimination half-life,"The model showed an age-related reduction in risperidone clearance (P < 0.0001), reduced renal elimination of 9-OH-risperidone (elimination half-life 27 h), and slower active moiety clearance in 22% of patients, (concentration-to-dose ratio: 20.2 (s.d. = 7.2) v. 7.6 (s.d. = 4.9) ng/mL per mg/day, Mann-Whitney U-test, P < 0.0001).",Towards safer risperidone prescribing in Alzheimer's disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176899/),h,27,209871,DB00734,Risperidone
,33176899,concentration-to-dose ratio,"The model showed an age-related reduction in risperidone clearance (P < 0.0001), reduced renal elimination of 9-OH-risperidone (elimination half-life 27 h), and slower active moiety clearance in 22% of patients, (concentration-to-dose ratio: 20.2 (s.d. = 7.2) v. 7.6 (s.d. = 4.9) ng/mL per mg/day, Mann-Whitney U-test, P < 0.0001).",Towards safer risperidone prescribing in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176899/),[ng] / [d·mg·ml],20.2,209872,DB00734,Risperidone
,33176899,concentration-to-dose ratio,"The model showed an age-related reduction in risperidone clearance (P < 0.0001), reduced renal elimination of 9-OH-risperidone (elimination half-life 27 h), and slower active moiety clearance in 22% of patients, (concentration-to-dose ratio: 20.2 (s.d. = 7.2) v. 7.6 (s.d. = 4.9) ng/mL per mg/day, Mann-Whitney U-test, P < 0.0001).",Towards safer risperidone prescribing in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176899/),[ng] / [d·mg·ml],7.6,209873,DB00734,Risperidone
,25099201,occupancy,Estimated dopamine D₂ occupancy (mean ± SD) decreased following dose reduction from 75.6% ± 4.9% to 66.8% ± 6.4% at peak and 72.3% ± 5.7% to 62.0% ± 6.8% at trough.,"Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25099201/),%,75.6,210192,DB00734,Risperidone
,25099201,occupancy,Estimated dopamine D₂ occupancy (mean ± SD) decreased following dose reduction from 75.6% ± 4.9% to 66.8% ± 6.4% at peak and 72.3% ± 5.7% to 62.0% ± 6.8% at trough.,"Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25099201/),%,66.8,210193,DB00734,Risperidone
,25099201,occupancy,Estimated dopamine D₂ occupancy (mean ± SD) decreased following dose reduction from 75.6% ± 4.9% to 66.8% ± 6.4% at peak and 72.3% ± 5.7% to 62.0% ± 6.8% at trough.,"Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25099201/),%,72.3,210194,DB00734,Risperidone
,25099201,occupancy,Estimated dopamine D₂ occupancy (mean ± SD) decreased following dose reduction from 75.6% ± 4.9% to 66.8% ± 6.4% at peak and 72.3% ± 5.7% to 62.0% ± 6.8% at trough.,"Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25099201/),%,62.0,210195,DB00734,Risperidone
,15710053,receptor occupancy,"After injections of 25, 50 and 75 mg on day 44 or day 71, D2 receptor occupancy ranged from 25-48%, 59-83% and 62-72% respectively, while plasma active-moiety levels ranged from 4.4-8.8, 15.0-31.1 and 22.5-26.3 ng/ml respectively.",Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15710053/),%,25-48,215766,DB00734,Risperidone
,15710053,receptor occupancy,"After injections of 25, 50 and 75 mg on day 44 or day 71, D2 receptor occupancy ranged from 25-48%, 59-83% and 62-72% respectively, while plasma active-moiety levels ranged from 4.4-8.8, 15.0-31.1 and 22.5-26.3 ng/ml respectively.",Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15710053/),%,59-83,215767,DB00734,Risperidone
,15710053,receptor occupancy,"After injections of 25, 50 and 75 mg on day 44 or day 71, D2 receptor occupancy ranged from 25-48%, 59-83% and 62-72% respectively, while plasma active-moiety levels ranged from 4.4-8.8, 15.0-31.1 and 22.5-26.3 ng/ml respectively.",Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15710053/),%,62-72,215768,DB00734,Risperidone
,15710053,plasma active-moiety levels,"After injections of 25, 50 and 75 mg on day 44 or day 71, D2 receptor occupancy ranged from 25-48%, 59-83% and 62-72% respectively, while plasma active-moiety levels ranged from 4.4-8.8, 15.0-31.1 and 22.5-26.3 ng/ml respectively.",Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15710053/),,4.4-8.8,215769,DB00734,Risperidone
,15710053,plasma active-moiety levels,"After injections of 25, 50 and 75 mg on day 44 or day 71, D2 receptor occupancy ranged from 25-48%, 59-83% and 62-72% respectively, while plasma active-moiety levels ranged from 4.4-8.8, 15.0-31.1 and 22.5-26.3 ng/ml respectively.",Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15710053/),[ng] / [ml],15.0-31.1,215770,DB00734,Risperidone
,15710053,plasma active-moiety levels,"After injections of 25, 50 and 75 mg on day 44 or day 71, D2 receptor occupancy ranged from 25-48%, 59-83% and 62-72% respectively, while plasma active-moiety levels ranged from 4.4-8.8, 15.0-31.1 and 22.5-26.3 ng/ml respectively.",Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15710053/),[ng] / [ml],22.5-26.3,215771,DB00734,Risperidone
,25404657,flow rate,"An isocratic mobile phase of acetonitrile:10 mM ammonium acetate (80:20, v/v) was used at the 0.3 mL/min flow rate.",A simple and fast UHPLC-MS-MS assay for rapid determination of vilazodone in plasma sample. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25404657/),[ml] / [min],0.3,215774,DB00734,Risperidone
,25404657,run time,"Both vilazodone and IS were eluted at 0.44 and 0.47 min, respectively, having a run time of 1.0 min.",A simple and fast UHPLC-MS-MS assay for rapid determination of vilazodone in plasma sample. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25404657/),min,1.0,215775,DB00734,Risperidone
,25404657,m/z,"The precursor to product ion transitions were monitored at m/z 442.19 > 154.99 for vilazodone and m/z 411.18 > 191.07 for IS, respectively.",A simple and fast UHPLC-MS-MS assay for rapid determination of vilazodone in plasma sample. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25404657/),,44,215776,DB00734,Risperidone
,25404657,m/z,"The precursor to product ion transitions were monitored at m/z 442.19 > 154.99 for vilazodone and m/z 411.18 > 191.07 for IS, respectively.",A simple and fast UHPLC-MS-MS assay for rapid determination of vilazodone in plasma sample. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25404657/),,154.99,215777,DB00734,Risperidone
,25404657,m/z,"The precursor to product ion transitions were monitored at m/z 442.19 > 154.99 for vilazodone and m/z 411.18 > 191.07 for IS, respectively.",A simple and fast UHPLC-MS-MS assay for rapid determination of vilazodone in plasma sample. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25404657/),,41,215778,DB00734,Risperidone
,25404657,m/z,"The precursor to product ion transitions were monitored at m/z 442.19 > 154.99 for vilazodone and m/z 411.18 > 191.07 for IS, respectively.",A simple and fast UHPLC-MS-MS assay for rapid determination of vilazodone in plasma sample. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25404657/),,191.07,215779,DB00734,Risperidone
,12469003,maximum concentration,The maximum concentration of unaltered RIS was 325 ng/mL and that of the principal metabolite (9-hydroxy-risperidone: 9-OH RIS) was 139 ng/mL.,Sequential changes in the plasma concentration of risperidone following intentional overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12469003/),[ng] / [ml],325,218561,DB00734,Risperidone
,12469003,maximum concentration,The maximum concentration of unaltered RIS was 325 ng/mL and that of the principal metabolite (9-hydroxy-risperidone: 9-OH RIS) was 139 ng/mL.,Sequential changes in the plasma concentration of risperidone following intentional overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12469003/),[ng] / [ml],139,218562,DB00734,Risperidone
,12469003,half-life,"By plotting the time-concentration curve for the active fraction (RIS plus 9-OH-RIS) in the first and second patients, the half-life of RIS following overdose was determined and was approximately 12.7 hr and 17.8 hr, respectively.",Sequential changes in the plasma concentration of risperidone following intentional overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12469003/),h,12.7,218563,DB00734,Risperidone
,12469003,half-life,"By plotting the time-concentration curve for the active fraction (RIS plus 9-OH-RIS) in the first and second patients, the half-life of RIS following overdose was determined and was approximately 12.7 hr and 17.8 hr, respectively.",Sequential changes in the plasma concentration of risperidone following intentional overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12469003/),h,17.8,218564,DB00734,Risperidone
,7530379,area under the plasma concentration curve (AUC) from 0 to 96 hours,"Following are the mean pharmacokinetics of risperidone and risperidone + 9-OH-risperidone: area under the plasma concentration curve (AUC) from 0 to 96 hours; 278.0 and 716.9 ng.hr/mL; AUC from 0 to infinity, 291.9 and 762.4 ng.hr/mL; peak plasma concentration, 33.0 and 44.5 ng/mL; time to peak concentration, 1.39 and 1.78 hours; and elimination half-life, 14.93 and 23.04 hours.",Pharmacokinetics of risperidone in chronic schizophrenic patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7530379/),[h·ng] / [ml],278.0,220826,DB00734,Risperidone
,7530379,area under the plasma concentration curve (AUC) from 0 to 96 hours,"Following are the mean pharmacokinetics of risperidone and risperidone + 9-OH-risperidone: area under the plasma concentration curve (AUC) from 0 to 96 hours; 278.0 and 716.9 ng.hr/mL; AUC from 0 to infinity, 291.9 and 762.4 ng.hr/mL; peak plasma concentration, 33.0 and 44.5 ng/mL; time to peak concentration, 1.39 and 1.78 hours; and elimination half-life, 14.93 and 23.04 hours.",Pharmacokinetics of risperidone in chronic schizophrenic patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7530379/),[h·ng] / [ml],716.9,220827,DB00734,Risperidone
,7530379,AUC from 0 to infinity,"Following are the mean pharmacokinetics of risperidone and risperidone + 9-OH-risperidone: area under the plasma concentration curve (AUC) from 0 to 96 hours; 278.0 and 716.9 ng.hr/mL; AUC from 0 to infinity, 291.9 and 762.4 ng.hr/mL; peak plasma concentration, 33.0 and 44.5 ng/mL; time to peak concentration, 1.39 and 1.78 hours; and elimination half-life, 14.93 and 23.04 hours.",Pharmacokinetics of risperidone in chronic schizophrenic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7530379/),[h·ng] / [ml],291.9,220828,DB00734,Risperidone
,7530379,AUC from 0 to infinity,"Following are the mean pharmacokinetics of risperidone and risperidone + 9-OH-risperidone: area under the plasma concentration curve (AUC) from 0 to 96 hours; 278.0 and 716.9 ng.hr/mL; AUC from 0 to infinity, 291.9 and 762.4 ng.hr/mL; peak plasma concentration, 33.0 and 44.5 ng/mL; time to peak concentration, 1.39 and 1.78 hours; and elimination half-life, 14.93 and 23.04 hours.",Pharmacokinetics of risperidone in chronic schizophrenic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7530379/),[h·ng] / [ml],762.4,220829,DB00734,Risperidone
,7530379,peak plasma concentration,"Following are the mean pharmacokinetics of risperidone and risperidone + 9-OH-risperidone: area under the plasma concentration curve (AUC) from 0 to 96 hours; 278.0 and 716.9 ng.hr/mL; AUC from 0 to infinity, 291.9 and 762.4 ng.hr/mL; peak plasma concentration, 33.0 and 44.5 ng/mL; time to peak concentration, 1.39 and 1.78 hours; and elimination half-life, 14.93 and 23.04 hours.",Pharmacokinetics of risperidone in chronic schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7530379/),[ng] / [ml],33.0,220830,DB00734,Risperidone
,7530379,peak plasma concentration,"Following are the mean pharmacokinetics of risperidone and risperidone + 9-OH-risperidone: area under the plasma concentration curve (AUC) from 0 to 96 hours; 278.0 and 716.9 ng.hr/mL; AUC from 0 to infinity, 291.9 and 762.4 ng.hr/mL; peak plasma concentration, 33.0 and 44.5 ng/mL; time to peak concentration, 1.39 and 1.78 hours; and elimination half-life, 14.93 and 23.04 hours.",Pharmacokinetics of risperidone in chronic schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7530379/),[ng] / [ml],44.5,220831,DB00734,Risperidone
,7530379,time to peak concentration,"Following are the mean pharmacokinetics of risperidone and risperidone + 9-OH-risperidone: area under the plasma concentration curve (AUC) from 0 to 96 hours; 278.0 and 716.9 ng.hr/mL; AUC from 0 to infinity, 291.9 and 762.4 ng.hr/mL; peak plasma concentration, 33.0 and 44.5 ng/mL; time to peak concentration, 1.39 and 1.78 hours; and elimination half-life, 14.93 and 23.04 hours.",Pharmacokinetics of risperidone in chronic schizophrenic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7530379/),h,1.39,220832,DB00734,Risperidone
,7530379,time to peak concentration,"Following are the mean pharmacokinetics of risperidone and risperidone + 9-OH-risperidone: area under the plasma concentration curve (AUC) from 0 to 96 hours; 278.0 and 716.9 ng.hr/mL; AUC from 0 to infinity, 291.9 and 762.4 ng.hr/mL; peak plasma concentration, 33.0 and 44.5 ng/mL; time to peak concentration, 1.39 and 1.78 hours; and elimination half-life, 14.93 and 23.04 hours.",Pharmacokinetics of risperidone in chronic schizophrenic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7530379/),h,1.78,220833,DB00734,Risperidone
,7530379,elimination half-life,"Following are the mean pharmacokinetics of risperidone and risperidone + 9-OH-risperidone: area under the plasma concentration curve (AUC) from 0 to 96 hours; 278.0 and 716.9 ng.hr/mL; AUC from 0 to infinity, 291.9 and 762.4 ng.hr/mL; peak plasma concentration, 33.0 and 44.5 ng/mL; time to peak concentration, 1.39 and 1.78 hours; and elimination half-life, 14.93 and 23.04 hours.",Pharmacokinetics of risperidone in chronic schizophrenic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7530379/),h,14.93,220834,DB00734,Risperidone
,7530379,elimination half-life,"Following are the mean pharmacokinetics of risperidone and risperidone + 9-OH-risperidone: area under the plasma concentration curve (AUC) from 0 to 96 hours; 278.0 and 716.9 ng.hr/mL; AUC from 0 to infinity, 291.9 and 762.4 ng.hr/mL; peak plasma concentration, 33.0 and 44.5 ng/mL; time to peak concentration, 1.39 and 1.78 hours; and elimination half-life, 14.93 and 23.04 hours.",Pharmacokinetics of risperidone in chronic schizophrenic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7530379/),h,23.04,220835,DB00734,Risperidone
,7530379,half-life,"These results demonstrate that the active moiety (risperidone plus 9-OH-risperidone) has a half-life of 23 hours and reveal a pool of risperidone (terminal half-life, 14.9 hours) that may allow twice-daily or even once-daily dosing.",Pharmacokinetics of risperidone in chronic schizophrenic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7530379/),h,23,220836,DB00734,Risperidone
,7530379,terminal half-life,"These results demonstrate that the active moiety (risperidone plus 9-OH-risperidone) has a half-life of 23 hours and reveal a pool of risperidone (terminal half-life, 14.9 hours) that may allow twice-daily or even once-daily dosing.",Pharmacokinetics of risperidone in chronic schizophrenic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7530379/),h,14.9,220837,DB00734,Risperidone
,33212399,m/z,"Detection was performed by multiple reactions monitoring with precursor-to-product ion transitions with m/z 411.2 → 191.0 for RISP, m/z 427.2 → 207.0 for 9-OH-RISP and m/z 260.1 → 116.0 for IS.",Systematic development of a bioanalytical UPLC-MS/MS method for estimation of risperidone and its active metabolite in long-acting microsphere formulation in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33212399/),,411.2,221334,DB00734,Risperidone
,33212399,m/z,"Detection was performed by multiple reactions monitoring with precursor-to-product ion transitions with m/z 411.2 → 191.0 for RISP, m/z 427.2 → 207.0 for 9-OH-RISP and m/z 260.1 → 116.0 for IS.",Systematic development of a bioanalytical UPLC-MS/MS method for estimation of risperidone and its active metabolite in long-acting microsphere formulation in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33212399/),,191.0,221335,DB00734,Risperidone
,33212399,m/z,"Detection was performed by multiple reactions monitoring with precursor-to-product ion transitions with m/z 411.2 → 191.0 for RISP, m/z 427.2 → 207.0 for 9-OH-RISP and m/z 260.1 → 116.0 for IS.",Systematic development of a bioanalytical UPLC-MS/MS method for estimation of risperidone and its active metabolite in long-acting microsphere formulation in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33212399/),,427.2,221336,DB00734,Risperidone
,33212399,m/z,"Detection was performed by multiple reactions monitoring with precursor-to-product ion transitions with m/z 411.2 → 191.0 for RISP, m/z 427.2 → 207.0 for 9-OH-RISP and m/z 260.1 → 116.0 for IS.",Systematic development of a bioanalytical UPLC-MS/MS method for estimation of risperidone and its active metabolite in long-acting microsphere formulation in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33212399/),,207.0,221337,DB00734,Risperidone
,33212399,m/z,"Detection was performed by multiple reactions monitoring with precursor-to-product ion transitions with m/z 411.2 → 191.0 for RISP, m/z 427.2 → 207.0 for 9-OH-RISP and m/z 260.1 → 116.0 for IS.",Systematic development of a bioanalytical UPLC-MS/MS method for estimation of risperidone and its active metabolite in long-acting microsphere formulation in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33212399/),,260.1,221338,DB00734,Risperidone
,33212399,m/z,"Detection was performed by multiple reactions monitoring with precursor-to-product ion transitions with m/z 411.2 → 191.0 for RISP, m/z 427.2 → 207.0 for 9-OH-RISP and m/z 260.1 → 116.0 for IS.",Systematic development of a bioanalytical UPLC-MS/MS method for estimation of risperidone and its active metabolite in long-acting microsphere formulation in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33212399/),,116.0,221339,DB00734,Risperidone
,33212399,lag-time,"Pharmacokinetic evaluation of the analytes from long-acting microparticles in rat plasma showed two peaks indicating an initial burst effect within 24 h of administration followed by controlled drug release pattern upto 45 days, while marketed formulation (Risperdal Consta®) showed no plasma concentration during the lag-time of 21 days followed by maximal drug absorption between 28 and 40 days.",Systematic development of a bioanalytical UPLC-MS/MS method for estimation of risperidone and its active metabolite in long-acting microsphere formulation in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33212399/),d,21,221340,DB00734,Risperidone
,33212399,maximal drug absorption,"Pharmacokinetic evaluation of the analytes from long-acting microparticles in rat plasma showed two peaks indicating an initial burst effect within 24 h of administration followed by controlled drug release pattern upto 45 days, while marketed formulation (Risperdal Consta®) showed no plasma concentration during the lag-time of 21 days followed by maximal drug absorption between 28 and 40 days.",Systematic development of a bioanalytical UPLC-MS/MS method for estimation of risperidone and its active metabolite in long-acting microsphere formulation in rat plasma. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33212399/),d,28 and 40,221341,DB00734,Risperidone
,15121646,occup,"The mean 5-HT(2) receptor occupancy was significantly higher than the mean D(2) receptor occupancy (mean=76%, SD=15%, and mean=56%, SD=18%, respectively).",A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15121646/),%,76,224901,DB00734,Risperidone
,15121646,occup,"The mean 5-HT(2) receptor occupancy was significantly higher than the mean D(2) receptor occupancy (mean=76%, SD=15%, and mean=56%, SD=18%, respectively).",A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15121646/),%,56,224902,DB00734,Risperidone
,17344104,LLOQ,LLOQ for all analytes was 0.2 ng/mL.,Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17344104/),[ng] / [ml],0.2,232764,DB00734,Risperidone
,17344104,sample run time,The sample run time was 8 min.,Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17344104/),min,8,232765,DB00734,Risperidone
,21118746,C(max),"For RSP, mean (SD) C(max) values were 12.6 (2.7) and 16.0 (2.3) ng/mL for the test and reference formulations, respectively.","Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21118746/),[ng] / [ml],12.6,234057,DB00734,Risperidone
,21118746,C(max),"For RSP, mean (SD) C(max) values were 12.6 (2.7) and 16.0 (2.3) ng/mL for the test and reference formulations, respectively.","Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21118746/),[ng] / [ml],16.0,234058,DB00734,Risperidone
,21118746,Cmax,"For 9-OH-RSP, mean Cmax values were 17.8 (1.3) and 21.0 (1.7) ng/mL for the test and reference formulations.","Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21118746/),[ng] / [ml],17.8,234059,DB00734,Risperidone
,21118746,Cmax,"For 9-OH-RSP, mean Cmax values were 17.8 (1.3) and 21.0 (1.7) ng/mL for the test and reference formulations.","Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21118746/),[ng] / [ml],21.0,234060,DB00734,Risperidone
,22335586,cumulative amount of drug permeated,"Among the tested preparations, formulations with 20% risperidone, 3:2 ERL 100 and ERS 100 as polymers, mixture of olive oil and jojoba oil as enhancer, exhibited greatest cumulative amount of drug permeated (1.87 ± 0.09 mg/cm(2)) in 72 h, so batch ROJ was concluded as optimized formulation and assessed for pharmacokinetic, pharmacodynamic and skin irritation potential.","Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22335586/),[mg] / [cm(2],1.87,237715,DB00734,Risperidone
,22335586,relative bioavailability,The calculated relative bioavailability of risperidone transdermal patch was 115.20% with prolonged release of drug.,"Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22335586/),%,115.20,237716,DB00734,Risperidone
,32476097,metabolic ratio,"One inpatient was identified as a potential PM, showing a metabolic ratio of 3.39.",Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32476097/),,3.39,239927,DB00734,Risperidone
,33400943,"AUC0-tau,ss","The AUC0-tau,ss of the active moiety (risperidone plus 9-OH-R) was 6.51 ± 3.34 in NMs and 7.00 ± 1.81 in IMs (P = 0.071) in the LY03004 group and 6.07 ± 2.31 and 7.95 ± 3.42 (P = 0.053) in NMs and IMs, respectively, in the Risperdal Consta® group.","Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400943/),,6.51,242360,DB00734,Risperidone
,33400943,"AUC0-tau,ss","The AUC0-tau,ss of the active moiety (risperidone plus 9-OH-R) was 6.51 ± 3.34 in NMs and 7.00 ± 1.81 in IMs (P = 0.071) in the LY03004 group and 6.07 ± 2.31 and 7.95 ± 3.42 (P = 0.053) in NMs and IMs, respectively, in the Risperdal Consta® group.","Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400943/),,7.00,242361,DB00734,Risperidone
,33400943,"AUC0-tau,ss","The AUC0-tau,ss of the active moiety (risperidone plus 9-OH-R) was 6.51 ± 3.34 in NMs and 7.00 ± 1.81 in IMs (P = 0.071) in the LY03004 group and 6.07 ± 2.31 and 7.95 ± 3.42 (P = 0.053) in NMs and IMs, respectively, in the Risperdal Consta® group.","Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400943/),,6.07,242362,DB00734,Risperidone
,33400943,"AUC0-tau,ss","The AUC0-tau,ss of the active moiety (risperidone plus 9-OH-R) was 6.51 ± 3.34 in NMs and 7.00 ± 1.81 in IMs (P = 0.071) in the LY03004 group and 6.07 ± 2.31 and 7.95 ± 3.42 (P = 0.053) in NMs and IMs, respectively, in the Risperdal Consta® group.","Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400943/),,7.95,242363,DB00734,Risperidone
,33400943,"Cmax,ss","In the LY03004 group, the Cmax,ss of risperidone in carriers of the ABCB1-C3435T TT variant was significantly lower than that in CC and CT carriers (TT 7.76 ± 4.23 ng/mL, CT 11.6 ± 8.27 ng/mL, CC 14.3 ± 7.66 ng/ml; P = 0.045), but no significant differences were found in the active moiety.","Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400943/),[ng] / [ml],7.76,242364,DB00734,Risperidone
,33400943,"Cmax,ss","In the LY03004 group, the Cmax,ss of risperidone in carriers of the ABCB1-C3435T TT variant was significantly lower than that in CC and CT carriers (TT 7.76 ± 4.23 ng/mL, CT 11.6 ± 8.27 ng/mL, CC 14.3 ± 7.66 ng/ml; P = 0.045), but no significant differences were found in the active moiety.","Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400943/),[ng] / [ml],11.6,242365,DB00734,Risperidone
,33400943,"Cmax,ss","In the LY03004 group, the Cmax,ss of risperidone in carriers of the ABCB1-C3435T TT variant was significantly lower than that in CC and CT carriers (TT 7.76 ± 4.23 ng/mL, CT 11.6 ± 8.27 ng/mL, CC 14.3 ± 7.66 ng/ml; P = 0.045), but no significant differences were found in the active moiety.","Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400943/),[ng] / [ml],14.3,242366,DB00734,Risperidone
,33400943,"Cmin,ss","In the Risperdal Consta® group, C3435T TT carriers had significantly lower Cmin,ss of the active moiety (TT 5.09 ± 4.38 ng/mL, CT 11.4 ± 8.42 ng/mL, CC 14.3 ± 6.43 ng/mL; P = 0.007).","Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400943/),[ng] / [ml],5.09,242367,DB00734,Risperidone
,33400943,"Cmin,ss","In the Risperdal Consta® group, C3435T TT carriers had significantly lower Cmin,ss of the active moiety (TT 5.09 ± 4.38 ng/mL, CT 11.4 ± 8.42 ng/mL, CC 14.3 ± 6.43 ng/mL; P = 0.007).","Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400943/),[ng] / [ml],11.4,242368,DB00734,Risperidone
,33400943,"Cmin,ss","In the Risperdal Consta® group, C3435T TT carriers had significantly lower Cmin,ss of the active moiety (TT 5.09 ± 4.38 ng/mL, CT 11.4 ± 8.42 ng/mL, CC 14.3 ± 6.43 ng/mL; P = 0.007).","Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400943/),[ng] / [ml],14.3,242369,DB00734,Risperidone
,20528007,apparent renal clearance of the active antipsychotic fraction,"Pooled population pharmacokinetic analysis, using a priori allometric scaling of the clearance and volume of distribution, showed that apparent renal clearance of the active antipsychotic fraction was 0.96 L/h and apparent metabolic clearance was 4.26 L/h for a typical patient weighing 62 kg, aged 18.1 years, with a median creatinine clearance of 117.6 mL/min.","Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20528007/),[l] / [h],0.96,246275,DB00734,Risperidone
,20528007,apparent metabolic clearance,"Pooled population pharmacokinetic analysis, using a priori allometric scaling of the clearance and volume of distribution, showed that apparent renal clearance of the active antipsychotic fraction was 0.96 L/h and apparent metabolic clearance was 4.26 L/h for a typical patient weighing 62 kg, aged 18.1 years, with a median creatinine clearance of 117.6 mL/min.","Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20528007/),[l] / [h],4.26,246276,DB00734,Risperidone
,20528007,apparent total oral clearance,"For a typical child (11 years, 39 kg), adolescent (15 years, 60 kg) and adult (33 years, 70 kg), the apparent total oral clearance values were 4.35, 5.30 and 5.04 L/h, respectively.","Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20528007/),[l] / [h],4.35,246277,DB00734,Risperidone
,20528007,apparent total oral clearance,"For a typical child (11 years, 39 kg), adolescent (15 years, 60 kg) and adult (33 years, 70 kg), the apparent total oral clearance values were 4.35, 5.30 and 5.04 L/h, respectively.","Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20528007/),[l] / [h],5.30,246278,DB00734,Risperidone
,20528007,apparent total oral clearance,"For a typical child (11 years, 39 kg), adolescent (15 years, 60 kg) and adult (33 years, 70 kg), the apparent total oral clearance values were 4.35, 5.30 and 5.04 L/h, respectively.","Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20528007/),[l] / [h],5.04,246279,DB00734,Risperidone
,18257133,recovery,The recovery of RIS from serum was in the range of 70.20% approximately 84.50%.,Determination of risperidone in human plasma by HPLC-MS/MS and its application to a pharmacokinetic study in Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18257133/),%,70.20,256036,DB00734,Risperidone
,18257133,recovery,The recovery of RIS from serum was in the range of 70.20% approximately 84.50%.,Determination of risperidone in human plasma by HPLC-MS/MS and its application to a pharmacokinetic study in Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18257133/),%,84.50,256037,DB00734,Risperidone
,29716869,relative bioavailability,"A combination of 6% menthol and 6% PG exhibited highest RIS in vitro penetration rate and showed a high efficiency in vivo, with a relative bioavailability of 131.53% compared with intragastric administration.",Delivery of risperidone from gels across porcine skin in vitro and in vivo in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29716869/),%,131.53,258368,DB00734,Risperidone
,11920159,plasma elimination half-lives,"Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D(2) receptor occupancy.",Significant dissociation of brain and plasma kinetics with antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920159/),h,24.2,260824,DB00734,Risperidone
,11920159,plasma elimination half-lives,"Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D(2) receptor occupancy.",Significant dissociation of brain and plasma kinetics with antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920159/),h,10.3,260825,DB00734,Risperidone
,11920159,plasma elimination half-lives,"Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D(2) receptor occupancy.",Significant dissociation of brain and plasma kinetics with antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920159/),h,75.2,260826,DB00734,Risperidone
,11920159,plasma elimination half-lives,"Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D(2) receptor occupancy.",Significant dissociation of brain and plasma kinetics with antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920159/),h,66.6,260827,DB00734,Risperidone
,18761856,half-life,Its half-life is about 24 hours.,[Paliperidone--a novel second-generation antipsychotic]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761856/),h,24,262513,DB00734,Risperidone
,16326078,window occupancy,"For conventional antipsychotics, the window occupancy is approximately 70-80%.","Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326078/),%,70-80,265444,DB00734,Risperidone
,20589922,t(max),"Paliperidone was well absorbed (median t(max): 24 h after a 3-mg dose, and 26 h after a 9-mg dose).",Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20589922/),h,24,267832,DB00734,Risperidone
,20589922,t(max),"Paliperidone was well absorbed (median t(max): 24 h after a 3-mg dose, and 26 h after a 9-mg dose).",Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20589922/),h,26,267833,DB00734,Risperidone
,20589922,t(1/2),"Pharmacokinetics was linear with respect to time; Geometric mean t(1/2) was 22.8 h and 21.4 h in 3-mg and 9-mg groups, respectively.",Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20589922/),h,22.8,267834,DB00734,Risperidone
,20589922,t(1/2),"Pharmacokinetics was linear with respect to time; Geometric mean t(1/2) was 22.8 h and 21.4 h in 3-mg and 9-mg groups, respectively.",Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20589922/),h,21.4,267835,DB00734,Risperidone
,17038872,plasma concentrations,"The mean plasma concentrations of olanzapine were 31 +/- 7 ng/mL at baseline, 32 +/- 7 ng/mL at week 6, and 36 +/- 9 ng/mL at week 10, the difference between week 10 and baseline being statistically significant (P < 0.05).","Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038872/),[ng] / [ml],31,272547,DB00734,Risperidone
,17038872,plasma concentrations,"The mean plasma concentrations of olanzapine were 31 +/- 7 ng/mL at baseline, 32 +/- 7 ng/mL at week 6, and 36 +/- 9 ng/mL at week 10, the difference between week 10 and baseline being statistically significant (P < 0.05).","Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038872/),[ng] / [ml],32,272548,DB00734,Risperidone
,17038872,plasma concentrations,"The mean plasma concentrations of olanzapine were 31 +/- 7 ng/mL at baseline, 32 +/- 7 ng/mL at week 6, and 36 +/- 9 ng/mL at week 10, the difference between week 10 and baseline being statistically significant (P < 0.05).","Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038872/),[ng] / [ml],36,272549,DB00734,Risperidone
,18771484,CL,"Population parameter estimates for CL in PM, IM and EM were 12.9, 36 and 65.4 l h(-1) and parameter estimates for risperidone half-life in PM, IM and EM were 25, 8.5 and 4.7 h, respectively.",Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771484/),[l] / [h],12.9,273082,DB00734,Risperidone
,18771484,CL,"Population parameter estimates for CL in PM, IM and EM were 12.9, 36 and 65.4 l h(-1) and parameter estimates for risperidone half-life in PM, IM and EM were 25, 8.5 and 4.7 h, respectively.",Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771484/),[l] / [h],36,273083,DB00734,Risperidone
,18771484,CL,"Population parameter estimates for CL in PM, IM and EM were 12.9, 36 and 65.4 l h(-1) and parameter estimates for risperidone half-life in PM, IM and EM were 25, 8.5 and 4.7 h, respectively.",Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771484/),[l] / [h],65.4,273084,DB00734,Risperidone
,18771484,half-life,"Population parameter estimates for CL in PM, IM and EM were 12.9, 36 and 65.4 l h(-1) and parameter estimates for risperidone half-life in PM, IM and EM were 25, 8.5 and 4.7 h, respectively.",Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771484/),h,25,273085,DB00734,Risperidone
,18771484,half-life,"Population parameter estimates for CL in PM, IM and EM were 12.9, 36 and 65.4 l h(-1) and parameter estimates for risperidone half-life in PM, IM and EM were 25, 8.5 and 4.7 h, respectively.",Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771484/),h,8.5,273086,DB00734,Risperidone
,18771484,half-life,"Population parameter estimates for CL in PM, IM and EM were 12.9, 36 and 65.4 l h(-1) and parameter estimates for risperidone half-life in PM, IM and EM were 25, 8.5 and 4.7 h, respectively.",Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771484/),h,4.7,273087,DB00734,Risperidone
,11981236,Steady-state plasma concentrations,"Steady-state plasma concentrations of CBZ increased from 6.67 +/- 0.41 microg/mL at baseline to 7.37 +/- 0.59 microg/mL (p < 0.01) at T1, to 7.95 +/- 0.47 microg/mL (p < 0.0001) at T2.",Carbamazepine-risperidone interactions in patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981236/),[μg] / [ml],6.67,273418,DB00734,Risperidone
,11981236,Steady-state plasma concentrations,"Steady-state plasma concentrations of CBZ increased from 6.67 +/- 0.41 microg/mL at baseline to 7.37 +/- 0.59 microg/mL (p < 0.01) at T1, to 7.95 +/- 0.47 microg/mL (p < 0.0001) at T2.",Carbamazepine-risperidone interactions in patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981236/),[μg] / [ml],7.37,273419,DB00734,Risperidone
,11981236,Steady-state plasma concentrations,"Steady-state plasma concentrations of CBZ increased from 6.67 +/- 0.41 microg/mL at baseline to 7.37 +/- 0.59 microg/mL (p < 0.01) at T1, to 7.95 +/- 0.47 microg/mL (p < 0.0001) at T2.",Carbamazepine-risperidone interactions in patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981236/),[μg] / [ml],7.95,273420,DB00734,Risperidone
